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ABSTRACT 
Given the widespread costs associated with alcohol use disorder (AUD; World Health 
Organization, 2011), it is unsurprising that many treatments exist for AUD. Moreover, 
many treatments have been rigorously studied via experimental research designs. In such 
research, treatment success has been defined predominantly as abstinence from alcohol 
or, more recently, no heavy drinking days. Consumption-based definitions of treatment 
success, rather than alternative non-consumption based definitions, have dominated in the 
field for at least two reasons. First, there are multiple measures of similar non-
consumption constructs (e.g., quality of life, psychosocial functioning), and very little 
research has been conducted to direct researchers toward the best non-consumption 
measures to use among AUD populations. Second, it is assumed that non-consumption 
measures are insensitive and, therefore, consumption must be used as a surrogate measure 
for more clinically meaningful non-consumption measures. The present research study 
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empirically addressed these two barriers that have thwarted attempts to shift toward 
including non-consumption variables in our definitions of treatment success. Using 
secondary data analysis of data collected from the COMBINE Study (Anton et al., 2006) 
and Project MATCH (Project MATCH Research Group, 1997), the present study 
conducted several tests of measurement stability, reliability, validity, sensitivity, and 
specificity. To test measurement stability the current study examined effect sizes and 
measurement invariance across time to test if non-consumption measures may be viable 
options for comparing pre- and post-treatment scores on these measures. The present 
study also conducted analyses on psychometric properties of extant measures: internal 
consistency reliability, construct validity, convergent validity. Finally, receiver operating 
characteristic curve analyses were conducted of total scale scores, subscales, and 
individual items when available and appropriate to test the sensitivity and specificity of 
non-consumption measures in detecting post-treatment and 12-month outcomes. The 
Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), and the brief World 
Health Organization Quality of Life measure (WHOQOL-BREF) were invariant across 
time and performed the best overall across all psychometric and sensitivity/specificity 
analyses conducted in the present manuscript. All other measures examined in the current 
study had at least some promising results, with the sole exception of the Addiction 
Severity Index (ASI), which had weak findings across all analyses. Moreover, some non-
consumption measures (e.g., Drinker Inventory of Consequences, Obsessive-Compulsive 
Drinking Scale) had baseline to post-treatment effect sizes as large as some consumption-
based outcome effect sizes. The results of the present study have identified gold standard 
measures for assessing mental health and quality of life. Future research should use the 
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BSI, BDI, and WHOQOL-BREF to examine clinically-relevant changes beyond 
consumption outcomes. The present findings also indicate that consumption measures 
may not be needed to serve as surrogates for these clinically relevant constructs. These 
findings represent the possibility of a paradigm shift in the field of AUD treatment 
research evaluation to incorporate non-consumption outcomes.  
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Introduction 
Background 
Alcohol misuse causes significant problems worldwide and affects the lives of 
millions of people. Recent estimates suggest excessive alcohol consumption and alcohol-
related problems comprise the third highest risk for disease and disability worldwide 
(World Health Organization, 2011). The prevalence of current (i.e., past twelve months) 
alcohol use disorder (AUD) in the United States has been estimated recently to be 13.9% 
(Grant et al., 2015). Given the prevalence of AUD and related public health concerns, 
research has focused on the development and evaluation of psychosocial and 
pharmacologic treatments for AUD. 
Historically, success in AUD treatment trials has been defined primarily by 
abstinence (binary outcome) or percentage of days abstinent (PDA, continuous outcome; 
Food and Drug Administration (FDA), 2006). The FDA (2015) recently proposed percent 
subjects with no heavy drinking days (PSNHDD), in addition to abstinence, as primary 
endpoints for evaluating AUD treatment trials, with “no heavy drinking days” defined as 
no days with 4/5 or more standard drinks for women/men (FDA, 2015). Other AUD 
treatment outcome definitions that are commonly used include: number of drinks per 
drinking day (DDD; e.g., Greenfield, 2000), drinks per day (DPD; e.g., Morgenstern et 
al., 2007); and frequency of heavy drinking (percent heavy drinking days, PHDD; e.g., 
Anton et al., 2006). Importantly all the outcomes commonly used to define treatment 
success (PDA, PSNHDD, DDD, DPD, PHDD) are consumption-based measures; thus, 
treatment success is often solely defined by whether a client is still drinking and/or how 
much alcohol an individual drinks. 
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Alcohol consumption, variously defined, has been the dominant outcome variable 
in AUD treatment research for a number of reasons. First, consumption variables are 
easily quantified using standard drinks, and a variety of consumption variables can be 
examined, including dichotomous (e.g., abstinent or not) and continuous variables (e.g., 
PDA, DDD). Second, alcohol consumption is tied inherently to the development of 
AUD—without consuming alcohol, it is impossible for one to develop AUD. Third, it has 
been argued that alcohol consumption is likely a surrogate measure for how an individual 
is functioning (FDA, 2015). However, relying upon consumption-based variables as the 
sole markers of treatment success is limited in substantial ways. 
Consumption-based outcome variables often fail to acknowledge the complex 
processes underlying the development, maintenance, and recovery from AUD. 
Recovering from addiction is more complex than simply abstaining from substance use, 
and defining treatment success purely by consumption often fails to adequately portray 
the complex, multifaceted recovery process (e.g., Donovan et al., 2012; Substance Abuse 
and Mental Health Services Administration, 2012; Tiffany et al., 2012). Cisler and 
Zweben (1999, 2003) attempted to address the need for a more complex representation of 
outcomes and created a composite measure to reconcile consumption with alcohol-related 
problems. This “composite clinical outcome” measure had four levels: (1) abstinence; (2) 
moderate drinking (<4 drinks for females; <6 drinks for males) without problems 
(drinking consequences occurred never or only once or twice); (3) heavy drinking (3+ 
occasions of 4+ drinks for females and 6+ drinks for males) or problems (recurrent 
drinking consequences occurring 3+ times); and (4) heavy drinking with problems. 
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Despite studies validating the composite clinical outcome measure (Cisler & Zweben, 
1999, 2003), this measure has never been widely adopted in the field. Recently, Kaskutas 
and colleagues (2014) developed a measure to identify specific components that were 
most important to how clients and their loved ones evaluated whether or not a client’s 
AUD had improved. Initial item testing and factor analysis indicated clients and their 
loved ones viewed a variety of non-consumption variables as important, including 
functioning and consequences (Kaskutas et al., 2014). Similarly, Neale and colleagues 
(2014) recently collected qualitative data to examine how treatment providers define 
treatment success. Findings suggest a broad range of outcomes are meaningful to 
treatment providers, including psychological and physical health, social functioning, and 
well-being (Neale et al., 2014). Thus, defining treatment success solely by consumption 
is an inaccurate definition of recovery from multiple clinically important perspectives. 
Defining treatment success by non-consumption outcome variables may also be 
more consistent with the variety of theoretical models of addiction that underlie AUD 
treatment development. Various theories (e.g., cognitive theory versus behavioral theory) 
posit different key outcomes (e.g., changes in thoughts versus behavior) and examining 
all AUD treatments primarily by consumption (e.g., PDA, PSNHDD), regardless of 
underlying theory or hypothesized mechanisms of change is inconsistent with the myriad 
of addiction models. Moos and Finney (1983) criticized this inconsistency and noted that 
theory should be used to guide treatment evaluation. Similarly, addictions researchers 
have called for the evaluation of theory-specific outcomes in substance use treatment 
research rather than a single, one-size-fit all outcome variable (Del Boca & Darkes, 2012; 
Donovan et al., 2012). Further, Moos and Finney (1983) called for a greater 
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acknowledgment of the complexities associated with AUD in AUD treatment research 
(i.e., AUD is not simply a phenomenon of using too much alcohol but rather one of 
consequences incurred by such alcohol use). In sum, the AUD treatment research 
community has recognized that AUD is complex and that research must account for such 
complexities to be consistent with theory in evaluating treatment. This recognition means 
moving beyond the singular approach of using consumption-based definitions of 
treatment success. 
Despite these arguments for shifting away from consumption as the sole index of 
AUD treatment success to more clinically and theoretically useful non-consumption 
measures, consumption outcomes have remained dominant in AUD treatment research. 
Efforts to incorporate non-consumption outcome measures into AUD treatment research 
have been stymied for at least two reasons. First, there are multiple measures of similar 
non-consumption constructs (e.g., quality of life), and research is needed to direct 
researchers toward the “gold standard” (i.e., psychometrically sound) measures that are 
viable for use among AUD populations (e.g., Del Boca & Darkes, 2012). Second, it is 
assumed that non-consumption measures are insensitive and, therefore, consumption 
must be used as a “surrogate” measure for more clinically meaningful non-consumption 
measures (FDA, 2015, p. 2). However, this assumption has not been subjected to 
empirical testing and some research has found non-consumption measures (e.g., 
temptation) to better predict AUD treatment outcomes (quantity, frequency, and alcohol-
related problems) than consumption-based measures (Witkiewitz, 2013). 
Present Study 
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The present study consisted of extensive secondary data analyses to evaluate and 
compare psychometric properties and the sensitivity/specificity of clinically meaningful 
non-consumption outcome variables (e.g., quality of life) for evaluating AUD treatment. 
To this end, the present study had two primary aims. Aim 1 was to examine the 
psychometric properties of several non-consumption self-report measures in order to 
explore the viability of these measures as potential “gold standard” measures to compare 
pre- and post-AUD treatment changes in these constructs. Accordingly, the present study 
conducted several tests of measurement stability, validity, and reliability. To test 
measurement stability the current study examined effect sizes and measurement 
invariance across time to test if non-consumption measures may be viable options for 
comparing pre- and post-treatment scores on these measures. Construct validity was 
examined via confirmatory factor analyses; convergent validity was examined via 
bivariate correlations with measures hypothesized to be related. These results informed 
further measure psychometric evaluation via examination of internal consistency total 
scale scores and sub-scale scores upheld via CFA and invariance testing. Aim 2 was to 
further test the viability of these non-consumption measures by examining total scale, 
subscale, and individual item sensitivity/specificity in an incremental approach based on 
CFA and invariance testing results and levels of sensitivity/specificity for each higher-
level score (i.e., individual items were only examined if subscales had adequate 
sensitivity/specificity). Together, results from Aims 1 and 2 highlighted non-consumption 
outcome measures that may be most appropriate for use in AUD treatment research 
contexts to define treatment success in clinically meaningful ways. 
Methods 
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Data 
The present study used data collected from the COMBINE Study (Anton et al., 
2006) and Project MATCH (Project MATCH Research Group, 1997). Table 1 
summarizes the participant demographics, design, and exclusion criteria used in these 
two studies. Psychometric, measurement invariance, and sensitivity/specificity analyses 
were conducted using measures that were consistent with the variables previously 
identified as important by researchers, clients and their loved ones, and treatment 
providers (Donovan, et al., 2012; Kaskutas et al., 2014; Neale et al., 2014) and included: 
1) drinking consequences/severity, 2) mental health, 3) craving/temptation, 4) quality of 
life/functioning. Table 2 details the measures used in these analyses and Figure 1 
summarizes the analyses conducted. These non-consumption variables were comprised of 
full-measure information (e.g., Drinker Inventory of Consequences (DrInC) total 
summary score; Miller, Tonigan, & Longabaugh, 1995) as well as sub-scale data when 
available (e.g., factor-analytically supported subscales of the DrInC) and individual-item 
analyses where applicable (e.g., individual items of the DrInC if DrInC subscales 
performed adequately). 
 COMBINE. COMBINE (N = 1383) was a large, multisite, randomized controlled 
trial of 9 treatment combinations of psychosocial interventions (Combined Behavioral 
Intervention (CBI) or Medication Management (MM)) and medication (acamprosate, 
naltrexone, or placebo). Assessments were conducted at baseline (i.e., pre-treatment), 
during treatment, and post-treatment follow-ups at 10-weeks (immediately post-treatment 
= “week 16” post-baseline), 9-months, and 12-months. Participants were all seeking 
treatment and were recruited from 11 research sites across the United States. Although 
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there were relatively few exclusion criteria (presented in Table 1: history of other 
substance use disorder except cannabis, psychiatric diagnoses requiring medication, 
unstable medical conditions), there were strict inclusion criteria in the COMBINE Study 
(Anton et al., 2006). All eligible participants must have 1) met criteria for Alcohol 
Dependence per the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV; American Psychiatric Association, 1994), 2) have had between 4 and 
21 days of abstinence prior to their baseline assessment session, and 3) have consumed > 
14/21 drinks per week (for women/men) with at least 2 heavy drinking days (> 4/5 drinks 
for women/men) within a consecutive 30 day period in the 90 days preceding their 
baseline assessment. These specific inclusion criteria resulted in greater homogeneity of 
alcohol consumption and problem severity in the COMBINE Study than those in Project 
MATCH. The sample homogeneity in COMBINE was intentional with the study design 
since the COMBINE Study was a pharmacotherapy study and selective recruitment was 
necessary to reduce medication complications. 
 Project MATCH. Project MATCH (N = 1726) was a large, multisite, randomized 
controlled trial of psychosocial treatments (Cognitive Behavioral Therapy (CBT), 
Motivational Enhancement Therapy (MET), or Twelve-Step Facilitation (TSF)). 
Participants were all seeking treatment and were provided 12 weeks of treatment. 
Assessments were conducted at baseline (i.e., pre-treatment), during treatment, and every 
three months post-treatment for up to 12 months. Participants were recruited from 9 
research sites across the United States. Participants received these treatments in either an 
aftercare arm (after release from an inpatient treatment) or an outpatient treatment arm. 
Participants were substantially different between these two treatment arm settings and 
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had significantly different outcomes post-treatment (Project MATCH Research Group, 
1998). Sample heterogeneity in Project MATCH was deliberate in the study design 
because the primary aim of MATCH was to find better treatment approaches to target 
client heterogeneity. A primary difference that resulted in differences in participant 
homogeneity between the COMBINE Study and Project MATCH was that Project 
MATCH inclusion criteria were DSM-III-R (American Psychiatric Association, 1987) 
diagnosis of alcohol abuse or dependence, whereas the COMBINE Study limited their 
sample to DSM-IV diagnoses of alcohol dependence only and had additional alcohol 
consumption inclusion criteria that were not paralleled in Project MATCH (Project 
MATCH Research Group, 1997). 
Measures 
 Alcohol-Related Variables. Both COMBINE and MATCH employed the Form 
90 (Miller, 1996) to collect 90-day assessment window information on daily drinking 
levels. From these data, multiple consumption outcome variables were computed: number 
of drinks per drinking day (DDD, including only days when alcohol was consumed), 
maximum number of drinks consumed in the 90-day window (MXD), drinks per day in 
the assessment window (DPD, averaging across drinking and abstinent days), binary 
heavy drinking (HD) data for each day, percent days abstinent (PDA), percent heavy 
drinking days (PHDD), World Health Organization risk levels (WHO risk levels; WHO, 
2000), and composite clinical score (abstinent, abstinent or moderate drinking without 
problems, heavy drinking/problems, or heavy drinking and problems; Cisler & Zweben, 
1999). WHO Risk levels included low risk (<20/40 grams of alcohol for women/men per 
day), medium risk (<40/60 grams of alcohol for women/men per day), high risk 
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(<60/<100 grams of alcohol for women/men per day) or very high risk (>60/100 grams of 
alcohol for women/men per day). Standard drinks were calculated using National 
Institute on Alcohol Abuse and Alcoholism guidelines of 14 grams. “Heavy drinking” 
was defined as 4/5 or more standard drinks for women/men (HD; NIAAA, 2004). The 
composite clinical score also used information collected in COMBINE and MATCH via 
the Drinker Inventory of Consequences (DrInC; Miller et al., 1995), a 45-item measure of 
alcohol-related consequences (plus 5 control-scale items not included in the present study 
analyses) on which higher scores indicated greater alcohol-consequence severity. The 
DrInC was initially conceptualized as containing 5 consequence factors: Interpersonal, 
Intrapersonal, Impulse Control, Physical, and Social Responsibility (Miller et al., 1995). 
It was according to these 5-factors that an abbreviated version of the DrInC was created: 
the Short Inventory of Problems (SIP; Feinn, Tennen, & Kranzler, 2003). Previously 
published findings have reported sufficient internal consistency reliability as well as 
convergent validity of the DrInC and the SIP in COMBINE and MATCH (α range from 
0.61 to 0.87 with the DrInC generally having higher internal consistency than the SIP; 
Forcehimes, Tonigan, Miller, Kenna, & Baer, 2007). Moreover, Marra and colleagues 
(2014) found strict measurement invariance between Spanish and English speakers for 
the SIP. However, multiple publications have proposed alternative factor structures, 
including 3- and 1-factor models for the DrInC and the SIP, which may indicate 
instability of previously examined factor solutions or poor construct validity of the DrInC 
and SIP administrations (e.g., Alterman, Cacciola, Ivey, Habing, & Lynch, 2009; Feinn et 
al., 2003; Hagman et al., 2009; Kenna et al., 2005). Of particular importance to the 
current analyses, in Project MATCH the DrInC was non-uniformly administered to 
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individuals who reported 100% days of abstinence during the follow-up assessments. 
Specifically, the items on the follow-up version of the DrInC are worded such that items 
should be endorsed only in reference to consequences that occurred due to drinking 
during the assessment window and some assessors in MATCH did not administer the 
DrInC to some, but not all, of the individuals who were abstinent at follow-up. This 
inconsistent administration of the DrInC in Project MATCH may have important impacts 
on how well it performs psychometrically across COMBINE and MATCH. 
 In addition to alcohol-related consequences, alcohol dependence severity was 
assessed in MATCH via the Addiction Severity Index (ASI; McLellan, Luborsky, 
Woody, & O’Brien, 1980). The ASI was created with a conceptualization of having 6-7 
factors: Medical Status, Employment/Social Support, Alcohol/Drug Use (sometimes 
conceptualized as separate factors), Legal Status, Family/Social, and Psychiatric Status 
(McLellan et al., 1992). However, other factor structures have also been published (e.g., 
Currie, El-Guebaly, Coulson, Hodings, & Mansley, 2004; Rogalski, 1987). 
Administrations of the ASI have found poor to good internal consistency of each of these 
factors (Currie et al., 2004) and other publications have cautioned against the use of the 
ASI as a research or diagnostic instrument (DeJong, Willems, Schippers, & Hendriks, 
1995). Project MATCH did not administer the full ASI that has been factor analyzed in 
previous studies and only included a partial set of items. 
 Also included in COMBINE and MATCH were measures of alcohol 
temptation/craving. In COMBINE, temptation/craving was measured by the Obsessive-
Compulsive Drinking Scale (Anton, 2000). The OCDS has been widely studied and 
conceptualized as a measure of alcohol craving (Anton, 2000) where higher scores 
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indicated greater alcohol craving, but various publications have found differing factor 
structures (e.g., Bohn, Barton, & Barron, 1996; Connor, Jack, Feeney, & Young, 2008; 
Connor, Feeney, Jack, & Young, 2010; Kranzler, Mulgrew, Modesto-Lowe, & Burleson, 
1999; Roberts, Anton, Latham, & Moak, 1999). In addition to unclear construct validity 
regarding differing published factor analytic results, there is mixed evidence of the 
convergent validity of administrations of the OCDS (e.g., Anton, Moak, & Latham, 1996; 
Connor et al., 2008; Moak, Anton, & Latham, 1998). Similarly, various administrations 
of the OCDS have yielded variable internal consistency of the overall measure and its 
factor analyzed subscales (e.g., Bohn et al., 1996; Kranzler et al., 1999). A slightly less-
studied measure that has been purported to measure temptation/craving is the Alcohol 
Abstinence Self-Efficacy Scale (AASE; DiClemente, Carbonari, Montgomery, & 
Hughes, 1994), which was administered in COMBINE and MATCH. The items in the 
AASE are worded to assess temptation/craving through the confidence an individual has 
in being able to avoid drinking in various circumstances. Therefore, lower AASE scores 
indicated higher temptation/craving to drink. Preliminary studies have identified the 
AASE as consisting of 4 factors related to situations in which individuals may be tempted 
to drink: Negative Affect, Social/Positive, Physical & Other Concern, Withdrawal or 
Urges (e.g., DiClemente et al., 1994; Hiller et al., 2000). Administrations of the AASE 
have demonstrated strong internal consistency reliability and modest convergent validity 
of total AASE score and each of the 4 subscales (DiClemente et al., 1994). In addition to 
the AASE, an individual item assessing overall temptation/craving was administered in 
MATCH. 
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 A final alcohol-related measure used in MATCH was the Alcoholics Anonymous 
Involvement scale (Tonigan, Connors, & Miller 1996). The AAI assesses for attendance 
of AA meetings as well as involvement with each of the 12-steps of AA. This measure 
was examined in the present study as a means of examining convergent validity of items 
hypothesized to be negatively or positively correlated with AA involvement. 
 Mental Health Variables. Mental health was assessed via multiple assessment 
measures in COMBINE and MATCH. In COMBINE, mental health was assessed via the 
Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983), which has been 
conceptualized as assessing 9 domains of mental health as well as overall global mental 
health problem severity; higher scores indicated greater mental health problem severity. 
These 9 domains have been upheld via numerous factor analyses, including analyses of 
the brief version of the BSI (BSI-18; e.g., Derogatis & Melisaratos, 1983; Long, Harring, 
Brekke, Test, & Greenberg, 2007; Recklitis et al., 2006; Wang et al., 2010). The BSI and 
BSI-18 have been administered in numerous mental health treatment studies and their 
psychometric properties (internal consistency, convergent validity) have been supported 
in multiple administrations of the measures. 
 A similarly well-studied measure of mental health is the Beck Depression 
Inventory (Beck, Steer, & Brown, 1996; Beck, Steer, & Garbin, 1988), which was 
administered in Project MATCH. The BDI and the second edition BDI-II measure 
depression symptoms, and higher levels indicated higher depression. The BDI and BDI-II 
have both been found to have either a 2- or a 3-factor structure and strong internal 
consistency and convergent validity in numerous measurement administrations (e.g., 
13 
 
 
Arnau, Meagher, Norris, & Bramson, 2001; Beck et al., 1988; Visser, Leentjens, 
Marinus, Stiggelbout, & van Hilten, 2006).  
 In addition to depression, mental health as a construct was also measured in 
Project MATCH via a state-trait anger expression inventory: the Spielberger State-Trait 
Inventory (SSTI; Forgays, Forgays, & Spielberger, 1997). Only a subset of items of the 
SSTI were administered in Project MATCH. Though few studies have been published 
regarding the psychometric properties of the SSTI, extant literature suggests the SSTI 
items administered in Project MATCH consist of two factors: a Temperament and a 
Reaction factor (Forgays et al., 1997; Kroner & Reddon, 1992; van der Ploeg, 1988). 
Previous findings have also indicated administrations of the SSTI have had at least 
acceptable internal consistency and convergent validity (Forgays et al., 1997; Kroner & 
Reddon, 1992; van der Ploeg, 1988). The SSTI was only administered at the baseline 
timepoint in MATCH. 
 Quality of Life/Functioning Variables. Quality of life was assessed in 
COMBINE via the World Health Organization Quality of Life, brief measure 
(WHOQOL-BREF; WHOQOL Group, 1998) and the Health Survey (SF-12; Ware, 
Kosinski, & Keller, 1996). The WHOQOL-BREF is an abbreviated version of the 100-
item WHOQOL where higher scores indicate better quality of life. Previous publications 
have identified the WHOQOL-BREF as comprised of a higher-order factor structure 
containing 4 lower-order factors (Physical Health, Psychological Health, Social 
Relationships, and Environment) and a higher-order Quality of Life factor (Skevington, 
Lofty, & O’Connell, 2004). One item of the WHOQOL-BREF assessing negative affect 
was erroneously omitted in administration of the WHOQOL-BREF in COMBINE. 
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Previous administrations of full version of the WHOQOL-BREF have been well-studied 
and have yielded good internal consistency, convergent validity, and measurement 
invariance across demographic groups (e.g., Jaracz, Kalfoss, Gorna, & Baczyk, 2006; 
Skevington et al., 2004; Yao & Wu, 2005).  
 The SF-12 is an abbreviated version of the SF-36, and has also been widely 
studied. However, unlike the WHOQOL-BREF there have been mixed findings regarding 
the psychometric properties of various SF-36 and SF-12 administrations (e.g., Hann & 
Reeves, 2008; Jakobsson, Westergren, Lindskov, & Hagell, 2012; Treanor & Donnelly, 
2015). The SF-12 is most often conceptualized as consisting of 2 factors: Physical Health 
and Psychological Health. Importantly, many of the items are “double-barreled,” 
meaning that a single item asks about both physical and mental health (e.g., “...how much 
of the time has your physical or emotional problems interfered with…”), which may 
mean participants are responding in different ways to the same item. The double-barreled 
nature of many of the SF-12 items may explain why construct validity of SF-12 
administrations have been variable across studies (Miller et al., 2009). Other 
psychometric properties of SF-12 administrations have been more consistently strong. 
The convergent validity of the SF-12 has been supported in previous administrations 
(e.g., Salyers, Bosworth, Swanson, Lamb-Pagone, & Osher, 2000) as well as the internal 
consistency (e.g., Montazeri, Vahdaninia, Mousavi, & Omidvari, 2009). Both the 
WHOQOL-BREF and the SF-12 are purported to measure non-disease-specific quality of 
life; however, neither have been extensively examined in samples of individuals with 
AUD. 
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 In Project MATCH, quality of life/psychosocial functioning was measured via the 
Psychosocial Functioning Inventory (PFI; Feragne, Longabaugh, & Stevenson, 1983). As 
described by Feragne and colleagues (1983), the PFI consists of 10 subscales and 2 
composite scales and higher scores on the PFI reflect better psychosocial functioning. An 
abbreviated version of the PFI was administered in Project MATCH and was coded 
according to three subscales: Subjective Role Performance, Overall Social Role 
Performance, and Housemate/Roommate Role (Project MATCH Research Group, 1997). 
Psychometric properties of the PFI have not been well studied in either the full or 
abbreviated forms. 
 A final metric for functioning that was used in COMBINE and MATCH consisted 
of items that assessed employment status and income (ESI). These items were included in 
the present study to examine convergent validity of other assessment tools. It was 
hypothesized that individuals who were functioning less well would have poorer 
employment status and lower income than individuals who were functioning well. Only a 
single, categorical item was used for employment status in COMBINE and MATCH and 
income was assessed in COMBINE but not MATCH. Further, the employment status 
item had to be re-coded in COMBINE and MATCH to facilitate more meaningful 
categories for analyses. Specifically, the COMBINE and MATCH employment items 
were recoded to represent increasing levels of employment: unemployment or disabled = 
0; homemaker, part-time employed, or retired = 1; and full-time employed = 2. 
COMBINE also included one item for income that was not paralleled in MATCH (< 
$15,000; $15,000 - $29,999; $30,000 - $59,000; $60,000 - $89,000; > $90,000). 
Aim 1 Analyses: Psychometric Properties 
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Extensive psychometric evaluation was conducted to help identify “gold-
standard” measures for non-consumption outcomes. All psychometric analyses were 
conducted in SPSS version 23 (IBM Corp, 2015) and Mplus version 7.3 (Muthén & 
Muthén, 2012). Missing data were handled with maximum likelihood estimation, 
multiple imputation, or mean-and-variance adjusted weighted least squares (WLSMV) 
estimation as recommended by Kline (2011) and described in detail below. Descriptive 
statistics (mean, standard deviation, frequencies) were computed in SPSS and then effect 
sizes (Cohen’s d; Cohen, 1988) were calculated per Lenhard and Lenhard (2016) to 
adjust for differences in sample sizes caused by attrition. A priori cutoffs for effect sizes 
were: large effect sizes d > 0.8, medium effect sizes 0.8 > d > 0.2, small effect sizes d < 
0.2 (Cohen, 1988). 
Although work has already been done to examine various psychometric properties 
of some of these measures (e.g., Forcehimes et al., 2007), some non-consumption 
measures have not been evaluated in AUD-specific samples (e.g., the construct validity 
of the WHOQOL-BREF) and the present analyses were more comprehensive than 
previous studies. The present analyses included examinations of the following for every 
non-consumption measure specified in Figure 1: effect sizes, internal consistency 
reliability, convergent validity, construct validity (via confirmatory factor analyses), and 
measurement invariance across time. Few studies have examined the measurement 
invariance of non-consumption measures across time. Identifying measures that are 
invariant over time is critical for advancing non-consumption outcome measures that may 
be used to evaluate AUD treatment outcomes, assuming the changes from baseline to end 
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of treatment reflect true changes in the construct of interest and not changes in the 
measurement over time. 
Construct Validity and Measurement invariance. In the present study, the 
construct validity of non-consumption measures was examined via confirmatory factor 
analysis (CFA) in the COMBINE Study and Project MATCH using baseline data to 
maximize sample size. CFA analyses were guided initially by factor structures that have 
been previously examined in prior studies. Data screening was conducted via SPSS 
version 23 (IBM Corp, 2015) to examine potential problems with the data prior to all 
analyses (e.g., nonnormality and outliers; Jackson, Gillaspy, & Purc-Stephenson, 2009). 
Specifically, measures with ordered categorical response options may yield data with 
rarely endorsed response categories and needed to be identified in data screening prior to 
CFA analyses.  
Although some have argued that factor analyses should maximize the ratio of 
participants to parameters to assure model stability (e.g., Gorsuch, 1983; Streiner, 1994), 
others have recommended the use of random split-half designs to test and replicate factor 
structures (Floyd & Widaman, 1995). Accordingly, CFAs were conducted using 
randomly split-half samples in Project MATCH and the COMBINE Study. The first half 
of the sample was used to find a model with acceptable model fit (defined below); the 
second half was used to replicate the model in an independent sample. Data were split 
randomly via SPSS version 23 (IBM Corp, 2015). Moreover, demographic differences by 
treatment site in MATCH and COMBINE were accounted for via clustering by treatment 
site in all CFA and measurement invariance analyses as recommended by Heck and 
Thomas (2009). Treatment site was accounted for using a sandwich estimator to calculate 
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the standard errors as recommended by Muthén and Muthén (2012) for handling complex 
survey data. The use of sandwich estimators to calculate standard errors is an alternative 
to multilevel modeling approaches for accounting for treatment site effects in complex 
survey data (Muthén & Muthén, 2012). 
 Hu and Bentler (1998) recommended evaluating CFA fit based on indices that 
have different properties such as incremental fit and residual-based fit. In the present 
study, model fit was examined via the comparative fit index (CFI), the Tucker-Lewis 
Index (TLI), and the root-mean-square error of approximation (RMSEA). The CFI and 
TLI are indices of incremental and relative fit whereas RMSEA is a residual-based fit 
index. Several researchers have recommended the CFI as an alternative to other fit 
indices such as the chi-square test of fit that are easily influenced by sample size (e.g., 
Floyd & Widaman, 1995). Marsh and colleagues (1988) recommended the TLI as a 
measure of relative fit that is robust to effects of large sample sizes based on the results of 
their Monte Carlo simulation study. Steiger and Lind (1980) provided justification for 
using RMSEA to evaluate model fit because it has a known distribution and is robust to 
problems associated with model complexity. Although some have advised against the use 
of “rules of thumb” for model fit (e.g., Marsh, Hau, & Wen, 2004; Yuan, 2005), others 
have argued that a priori fit indices cutoffs are important to retain objectivity in model 
evaluation (Jackson et al., 2009). Accordingly, a priori cutoffs for the above fit indices 
were used, as informed by Hu & Bentler (1999) and Browne & Cudeck (1993) in order to 
minimize Type I and Type II error rates and reflect good model fit: CFI > 0.95; TLI > 
0.95; RMSEA < 0.06. Acceptable model fit a priori cutoffs were CFI > 0.90; TLI > 0.90; 
RMSEA < 0.08. Fit indices outside of these cutoffs were deemed inadequate. 
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 Inadequate model fit statistics in the CFAs prompted exploration of alternative 
factor structures. First, individual items within each measure were examined to identify 
common themes of question items. If face-valid themes were identifiable in this method, 
alternative factor structures were tested using CFA and the methodology described above 
regarding split-half and a priori fit cutoffs. If these models failed to provide adequate fit 
or there were no easily identifiable themes across items, exploratory factor analyses 
(EFA) were employed to examine alternative factor solutions. As recommended by Floyd 
and Widaman (1995), EFA using principal factor analysis (PFA) was used to explore the 
relationships among observed variables relative to underlying latent variables. We 
anticipated non-zero correlations among the latent factors for the analyzed measures, thus 
oblique rotation methods were used to allow for correlations between factors (e.g., 
geomin rotation; Floyd & Widaman, 1995).  
 The number of factors to be tested via CFA, based on EFA results, was 
determined by parallel analysis and the scree plot. As recommended by several 
publications (e.g., Floyd & Widaman, 1995; Gorsuch, 1983; Zwick & Velicer, 1986), the 
elbow in the scree plot of the eigenvalues was used to indicate the number of factors. If 
there were multiple points that could constitute an “elbow,” alternative factor solutions 
were tested at each of these potential elbows. Notably, visual inspections of the scree plot 
of EFA results have demonstrated satisfactory performance and are generally less biased 
than reliance upon the Kaiser-Guttman rule of retaining all factors with eigenvalue > 1, 
especially when combined with a parallel-analysis of the eigenvalues against what might 
be expected by chance alone (Montanelli & Humphreys, 1976). Accordingly, scree plot 
and parallel analysis guided factor enumeration for EFAs. These factor solutions were 
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then tested via CFA as described above. Since items are allowed to be explained by 
multiple factors in EFA, item-factor assignment was based on the factor on which the 
item loaded strongest or where the item made most conceptual sense. However, if an item 
failed to load > 0.40 on any factor, that item was omitted from further analyses given 
research on the instability of factor solutions derived using items that load with factor 
loadings < 0.40 (Guadagnoli & Velicer, 1988). When models informed thusly by EFA 
results failed to provide adequate fit in CFA as defined by a priori cutoffs above, factor 
analyses were ceased for that measure and invariance testing was not pursued. 
 When an adequately fitting factor-solution was found and replicated in 
independent split-half sub-samples, measurement invariance across time was tested by 
examining nested models between baseline and post-treatment datasets. Measurement 
invariance over time was tested for possible non-equivalence of measurement parameters 
(e.g., item intercepts, item loadings) over time (Widaman et al., 2010). Specific 
procedures to test longitudinal measurement invariance followed the recommendations of 
Vandenberg and Lance (2000) based on the results of their literature review. First, an 
omnibus test of the equality of covariance matrices across time was tested. Next, 
configural invariance was tested wherein the overall factor structure is tested as 
equivalent across time (Horn & McArdle, 1992). Then, metric invariance was tested by 
constraining the factor loadings to be equivalent across time (Horn & McArdle, 1992). 
Next, thresholds were constrained to equality across time to establish scalar invariance 
(i.e., “strong invariance”). Since Widaman and colleagues (2010) argued that strong 
factorial invariance must be held across time to identify a consistent latent construct, 
analyses attempted to test at least partial scalar invariance by allowing some of the 
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constraints to be freed. Decisions to free constraints were based on a combination of what 
made conceptual sense to free based on item question content and modification indices 
(Vandenberg & Lance, 2000). Residual invariance (i.e., “strict invariance;” Widaman et 
al., 2010) was not tested in the current study because all measures had categorical items 
(mostly Likert-type scales) and residuals were necessarily constrained to 1 for model 
identification. Thus, additional equality constraints could not be examined. 
 In the cases where a measure had a higher-order factor structure, analyses 
followed the procedures for testing measurement invariance as specified by Chen and 
colleagues (2005). In this procedure, configural invariance across time of the full model 
was tested. Next, invariance of factor loadings in only the lower-order factor level was 
tested. Then, invariance of factor loadings in both the lower- and higher-order factor 
levels were analyzed. Once configural invariance was established, analyses included the 
additional constraint of equal intercepts of the observed variables across time. Next, 
analyses included the additional constraint of the intercepts of the lower-level factors to 
equivalence and then constrained the disturbances of the lower-level factors to be 
equivalent across time.  
To determine if a more stringent level of invariance fit significantly worse than a 
less stringent level of invariance (i.e., to determine the level of invariance or non-
invariance), analyses used the recommendations of Widaman and colleagues (2010) and 
synthesized the information provided by the fit indices (specifically, the CFI, TLI, and 
RMSEA). As noted by Cheung and Rensvold (2002) among others, chi-square difference 
testing is influenced by large sample sizes and may be too sensitive for measurement 
invariance testing with large samples like those in COMBINE and MATCH. Thus, chi-
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square difference testing was not used in the present study. Instead, measurement 
invariance results were evaluated based on changes in CFI, TLI, and RMSEA or 
inadequate CFI, TLI, and/or RMSEA fit indices as indicators of poorer model fit across 
time (i.e., longitudinal measurement non-invariance). Many recommend against using 
“rules of thumbs” for fit statistics and overall change in fit across CFI, TLI, and RMSEA 
together was considered for determining measurement invariance or non-invariance (e.g., 
Vandenberg & Lance, 2000; Widaman et al., 2010). Some, however, suggest that a 
change (decrease) in CFI and TLI of greater than .01 and .0.5, respectively, from one 
level of invariance to another indicates the factor structure may be non-invariant (Cheung 
& Rensvold, 2002). Accordingly, these rules of thumbs were considered in evaluating 
change in fit statistics, but were not held as the sole determinants of non-invariance. 
Reliability. Internal consistency reliability was examined via Cronbach’s alpha of 
both total scale scores (e.g., DrInC summary score) and subscale scores (e.g., subscales 
of the DrInC) when available and applicable (i.e., when subscales were verified via factor 
analyses). Cronbach’s alpha values closer to 1 indicated better internal consistency. 
Convergent Validity. Convergent validity was examined via bivariate 
correlations of a given measure with measures that purport to measure similar and 
opposite constructs. See Table 3 for measures that were hypothesized to possess 
convergent validity (i.e., predicted significant positive or negative correlations with 
conceptually similar or dissimilar constructs). 
Aim 2 Analyses: Sensitivity/Specificity  
Receiver Operating Characteristic (ROC) curve analyses. Secondary data 
analyses of the COMBINE and MATCH data were conducted to examine the sensitivity 
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and specificity of the non-consumption outcome variables using ROC curve analyses 
(Hanley & McNeil, 1982). ROC curve analyses stem from signal detection theory where 
“sensitivity” is the ability of a measure to detect a signal (i.e., outcome) and “specificity” 
refers to the ability of a measure to discriminate between the target signal and other 
signals or noise. ROC curve analyses have been used extensively in other literatures, 
especially in the medical field for diagnostic testing (e.g., radiology; Hanley & McNeil, 
1982). The ROC curve results were evaluated using the area under the curve (AUC) 
where measures with AUC = 1 are considered perfectly sensitive/specific to detection and 
discrimination of the target outcome variable and AUC < 0.50 are considered poor 
(Bradley & Longstaff, 2004). Generally, AUC values > 0.65 are considered adequately 
sensitive/specific (Egger & Borg, 2016). Although AUC reflects an ability to both 
accurately detect and discriminate a target outcome variable, for parsimony of language, 
AUC results will be described using “detection” language throughout the manuscript. 
All ROC curve analyses were conducted using non-consumption outcomes 
assessed at the assessment timepoint that immediately followed treatment in each study 
(4-month (i.e., “week-16”) follow-up in COMBINE and 3-month follow-up in MATCH). 
These analyses examined how sensitive/specific each variable is at detecting binary 
outcomes at two timepoints: 4- or 3-months post-treatment and 12-months post-treatment 
for: 1) abstinence versus any drinking, 2) no heavy drinking days versus any heavy 
drinking days (Falk et al., 2010), 3) the World Health Organization risky drinking levels 
[European Medicines Agency, 2010; with three cutoffs: (a) low risk (<20/40g alcohol for 
women/men per day), (b) medium risk (<40/60g alcohol for women/men), and c) high 
risk or very high risk (>41/61g alcohol for women/men; English et al., 1995); all risk 
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levels were calculated via DDD, MXD, and DPD], and 4) scores on a composite clinical 
outcome measure of alcohol-related problems and consumption [Cisler & Zweben, 1999; 
with four cutoffs: a) abstinent, b) abstinent or moderate drinking without problems, c) 
heavy drinking/problems, and d) heavy drinking and problems]. As a further test of WHO 
risk levels, ROC curve analyses were also conducted for non-consumption variables’ 
sensitivity/specificity for changes in WHO risk level between baseline and post-treatment 
(1+ and 2+ risk level changes, calculated via DDD and DPD). The results from the non-
consumption variables ROC curve analyses were compared to those of the most widely 
used consumption-based measures (PDA and PHD) to understand if non-consumption 
outcomes were substantially less sensitive compared to consumption outcomes. Analyses 
were conducted separately in COMBINE and MATCH to examine the cross validation of 
findings whenever possible.  
For measures with subscale factor structures that were upheld via the CFA results, 
ROC curve analyses were conducted for each subscale. When AUC > 0.65 for subscales 
on at least one of the outcomes tested, individual item ROC curves were analyzed to try 
to identify individual items most sensitive/specific to the evaluated outcomes. Given the 
extensive number of items, we report the results from item level ROC curve analyses in 
Appendix A. 
Summary of Analyses 
 In order to synthesize the myriad results of the present study, results were distilled 
and summarized using a 2-point system. Measures that had poor sensitivity/specificity, 
psychometric properties, or measurement invariance were allocated 0 points; those with 
mixed or modest properties were allocated 1 point. Measures with acceptable to excellent 
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sensitivity/specificity, psychometric properties, or measurement invariance were 
allocated 2 points. Sensitivity/specificity scores of 0 indicated area under the curve 
(AUC) < 0.650 across all outcomes; 1 point indicated AUC > 0.650 and < 0.700 or mixed 
results across studies or across consumption outcomes; 2 points indicated AUC > 0.700 
in both COMBINE and MATCH or for most outcomes. Internal consistency reliability 
scores of 0 indicated α < 0.70; 1 point indicated α > 0.70 and < 0.80 or mixed results 
across studies; 2 points indicated α > 0.80 in both COMBINE and MATCH. Convergent 
validity results with scores of 0 indicated non-significant (p > 0.05) or at least one 
correlation in the opposite direction than was expected; 1 point indicated significant 
correlations with some but not all the expected measures or mixed results across studies; 
2 points indicated significant correlations in the expected direction for all measures in 
both COMBINE and MATCH. Confirmatory factor analysis (CFA) results with scores of 
0 indicated RMSEA > 0.08 or CFI or TLI < 0.90; 1 point indicated RMSEA < 0.08 and > 
0.06 and/or CFI or TLI > 0.90 and < 0.95 or mixed results across studies; 2 points 
indicated RMSEA < 0.06 and CFI or TLI > 0.95 in both COMBINE and MATCH. 
Measurement invariance results with scores of 0 indicated non-invariance at the 
configural level or did not proceed to invariance testing due to poor model fit; 1 point 
indicated at least adequate model fit through the metric invariance testing (constraint of 
the factor loadings for equivalence) or mixed results across both studies; 2 points 
indicated good model fit through strong invariance testing (highest possible level of 
invariance for categorical data) in both COMBINE and MATCH. 
Results 
Descriptive Results 
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 Descriptive analyses of the data are presented in Tables 4 and 5. As depicted in 
Table 4, consumption outcome descriptives were largely similar between COMBINE and 
MATCH datasets. The percent days abstinent (PDA) were slightly higher at all 
timepoints in MATCH (baseline mean = 30.90% (SD =29.96%), N = 1725); post-
treatment mean = 83.17% (SD = 28.51%), N = 1657; 12-month follow-up mean = 
76.69% (SD = 33.55%), N = 1594) compared to COMBINE (baseline mean = 21.41% 
(SD = 22.50%), N = 1383); post-treatment mean = 72.66% (SD = 33.49%), N = 1288; 
12-month follow-up mean = 62.63% (SD = 39.12%), N = 1099). Similarly, the percent 
heavy drinking days (PHDD) was higher in COMBINE (baseline mean = 70.52% (SD = 
26.57%), N = 1383); post-treatment mean = 17.54% (SD = 28.69%), N = 1288; 12-month 
follow-up mean = 26.20% (SD = 34.27%), N = 1171) at all timepoints compared to 
MATCH (baseline mean = 63.18% (SD = 31.43%), N = 1725); post-treatment mean = 
12.46% (SD = 25.09%), N = 1657; 12-month follow-up mean = 16.71% (SD = 29.17%), 
N = 1594). These consumption variables were also consistent across both COMBINE and 
MATCH in that the largest differences between timepoints occurred from baseline to 
post-treatment and from baseline to 12-month follow-up, as evidenced by very large 
effect sizes (d > 1.0) for difference from baseline and effect sizes around 0.2 in both 
COMBINE (d = 0.277 for PDA and d = 0.275 for PHDD) and MATCH (d = 0.208 for 
PDA and d = 0.156 for PHDD) for post-treatment to 12-month follow-up. 
 The pattern of change observed with consumption outcomes PDA and PHDD, 
whereby the smallest changes occurred between post-treatment and 12-month follow-up 
and the largest changes occurred between baseline and post-treatment and also between 
baseline and 12-month follow-up, was consistent with change patterns in the non-
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consumption measures (see Table 4). However, there were differences in descriptive 
statistics for measures used in COMBINE versus MATCH. Similar to the different rates 
of abstinence and heavy drinking days, COMBINE and MATCH differed slightly with 
regards to their overall sample’s endorsement of alcohol-related consequences on the 
Drinker Inventory of Consequences (DrInC) at each timepoint and for each of the 5 
commonly used subscales. In COMBINE, the overall DrInC average summary score at 
baseline was 47.61 (SD = 20.42; N = 1381; baseline to post-treatment d = 1.735), at post-
treatment was 13.36 (SD = 18.85; N = 1098; post-treatment to 12-month d = 0.322), and 
at 12-month follow-up was 19.89 (SD = 21.81; N = 965; baseline to 12-month d = 1.320). 
In contrast, for MATCH the overall DrInC average summary score at baseline was 52.63 
(SD = 23.32; N = 1703; baseline to post-treatment d = 0.680), at post-treatment was 35.86 
(SD = 26.78; N = 985; post-treatment to 12-month d = 0.323), and at 12-month follow-up 
was 27.50 (SD = 24.70; N = 789; baseline to 12-month d = 1.057). Higher DrInC scores 
in Project MATCH were likely due to the different administration procedures for 
COMBINE and MATCH with the DrInC, whereby the DrInC was administered to all 
abstainers in COMBINE and only some of the abstainers in MATCH. Similar patterns are 
observed in the commonly used subscales (physical health consequences, interpersonal 
consequences, intrapersonal consequences, impulse control, and social responsibility) of 
the DrInC for COMBINE and MATCH and effect sizes were generally higher in 
COMBINE overall. Effect sizes differed between COMBINE and MATCH in that the 
greatest changes in subscale scores occurred from baseline to post-treatment in 
COMBINE whereas the largest effect sizes in MATCH occurred baseline to 12-month 
follow-up. These changes may reflect the overall sample differences between COMBINE 
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and MATCH and the fact that overall sample was used for descriptive analyses rather 
than sub-samples (e.g., treatment arms in MATCH were not examined separately). 
 Other noteworthy findings from descriptive analyses were that effect sizes were 
found to be very large for several of the non-consumption measures and that these effects 
were on-par with those found for the primary consumption outcome variables of PDA 
and PHDD. For instance, the baseline to post-treatment effect size of the Obsessive-
Compulsive Drinking Scale (OCDS) in COMBINE was d = 1.762, which is larger than 
the congruent effect size of the DrInC in COMBINE. Effect sizes of the Alcohol 
Abstinence Self-Efficacy Scale in COMBINE and MATCH were small for the total 
AASE; however, effect sizes were much larger when examining the Confidence and 
Temptation subscales independently. In COMBINE, the baseline to post-treatment effect 
sizes were d = 1.078 and d = 1.022 for the Confidence and Temptation subscales, 
respectively. These scores were noticeably smaller in MATCH: d = 0.469 and d = 0.674, 
respectively. The remaining measures had smaller effect sizes, although many effect sizes 
were still notable and were in the medium range (0.2 < d < 0.8; Cohen, 1988). 
Importantly, analysis of the descriptive statistics highlighted differences between 
COMBINE and MATCH that may reflect the overall sample differences between 
COMBINE and MATCH and the fact that overall sample was used for descriptive 
analyses rather than sub-samples (e.g., treatment arm).  
Descriptive analyses also indicated the potential for problems with factor analyses 
given large standard deviations in some of the measures. Most notably, the Addiction 
Severity Index yielded very large standard deviations, especially for the family history 
(mean = 2.65, SD = 48.04, N = 1726) and legal status (mean = 141.90, SD = 384.71, N = 
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1726) subscales. Moreover, since the Psychiatric status mean scores were < 1 at all three 
timepoints at which this subscale was uniquely administered, descriptive analyses 
suggested combining psychiatric, family history, and legal status questions into one ASI 
summary score may be problematic given the range in responses possible for each 
subscale. These descriptive statistics and effect sizes provide a potentially useful 
overview of the performances of each measure in COMBINE and MATCH. 
Descriptive results not presented in Table 4 are those for employment status and 
income (ESI) items used in COMBINE and MATCH. Employment status descriptives 
were: unemployment or disabled = 0 (n = 225 in COMBINE, 478 in MATCH), 
homemaker, part-time employed, or retired = 1 (n = 253 in COMBINE, 282 in MATCH), 
full-time employed = 2 (n = 838 in COMBINE, 847 in MATCH). COMBINE also 
included one item for income that was not paralleled in MATCH (< $15,000, n = 139; 
$15,000 - $29,999, n = 219; $30,000 - $59,000, n = 408; $60,000 - $89,000, n = 266; > 
$90,000, n = 330). These items indicate fairly even distribution of responses and again 
highlight important demographic differences between COMBINE and MATCH. 
 A final descriptive overview of the variables examined in the present study is 
provided by Table 5, which depicts the frequencies of the binary consumption outcome 
variables that were examined in the Receiver Operating Characteristic (ROC) curve 
analyses. Although base rate is mathematically unrelated to sensitivity and specificity 
(Pepe, 2003), the rates of each consumption outcome are interesting to consider in 
comparison to one another. Perhaps most notably, the rates of each of the World Health 
Organization Risk levels vary depending on how the risk levels were calculated (i.e., via 
Drinks per Drinking Day (DDD), Maximum number of drinks consumed in the 90-day 
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window (MXD), or via drinks per day in the assessment window (averaged across 
drinking and abstinent days; DPD)). For instance, the number of participants categorized 
as moderate or lower risk in COMBINE at post-treatment was: n=744, n=647, or n=1089 
depending on if that risk level was calculated via DDD, MXD, or DPD, respectively.  
Summary of Analyses 
 The overall results from the core analyses of the present study are depicted in 
Table 6 and highlight that no measure performed excellently across all examined 
domains. The Brief Symptom Inventory and Beck Depression Inventory performed best, 
with 2 points allocated for all examined properties except sensitivity/specificity, for 
which only 1 point was allocated due to mixed results. Similarly, the WHOQOL-BREF 
performed well and had 2 points allocated for all except CFA results, which fit 
adequately, and sensitivity/specificity, which were unable to be compared to other 
measures since WHOQOL-BREF administration occurred after the post-treatment 
timepoint in COMBINE. The remaining measures all had at least some promising 
qualities and are described below in order of how well they performed (best performance 
to poorest performance). The only measure examined in the present study that received 0 
points for “poor” properties across all analyses was the Addiction Severity Index. These 
results were consistent with the fact that the full ASI was not used in MATCH and, more 
importantly, that the measure may be most helpful as an inventory of historical events 
(e.g., number of times incarcerated for various offenses, number of family members with 
histories of alcohol problems) rather than a measure that may hold utility for comparing 
scores pre- and post-treatment. 
Strongest Results  
31 
 
 
 Brief Symptom Inventory. The Brief Symptom Inventory was originally 
conceptualized as containing 9-factors with higher scores indicating more severe 
psychological symptoms: Somatization, Obsessive-Compulsive, Depression, 
Interpersonal Sensitivity, Hostility, Anxiety, Psychoticism, Phobic Anxiety, and Paranoid 
Ideation (Derogatis & Melisaratos, 1983). This 9-factor structure was upheld in the 
COMBINE study via CFA (replication half fit indices: RMSEA = 0.022 (90% CI: 0.019, 
0.025); CFI = 0.975; TLI = 0.974; presented in Table 7). Moreover, this factor structure 
was invariant across time between baseline and post-treatment (week 16) timepoints in 
COMBINE. The configural model of invariance testing fit very well (RMSEA = 0.011 
(90% CI: 0.010, 0.012); CFI = 0.981; TLI = 0.980), as did tests of metric invariance 
(RMSEA = 0.011 (90% CI: 0.009, 0.012); CFI = 0.982; TLI = 0.981), and strong 
invariance (RMSEA = 0.012 (90% CI: 0.011, 0.013); CFI = 0.977; TLI = 0.977). 
Moreover, as presented in Table 8, internal consistency reliability of the BSI and 9 factor 
subscales varied from good to excellent, with the sole exception of the Interpersonal 
Sensitivity subscale: total BSI α = 0.965, Somatization subscale α = 0.798, Obsessive-
Compulsive subscale α = 0.862, Depression subscale α = 0.882, Interpersonal Sensitivity 
subscale α = 0.643, Hostility subscale α = 0.790, Anxiety subscale α = 0.824, 
Psychoticism subscale α = 0.864, Phobic Anxiety subscale α = 0.786, and Paranoid 
Ideation subscale α = 0.836. The BSI also had good convergent validity and all bivariate 
correlations were significant (p < 0.01) in the direction predicted. Specifically, the BSI 
was significantly, negatively correlated with quality of life (WHOQOL-BREF: r = -
0.698, p < 0.001; SF-12: r = -0.688, p < 0.001), recoded employment status (ESI 
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employment item: r = -0.189, p < 0.001), and income (ESI income item: r = -0.211, p < 
0.01).  
 The BSI also had modest sensitivity/specificity, as indicated by ROC curve 
results, as detailed in Table 9. The post-treatment BSI total summary score adequately 
detected 9 of 15 post-treatment consumption outcomes (AUC > 0.650), however only 
detected 1 of 11 12-month follow-up consumption outcomes (AUC > 0.650). The total 
BSI summary score had the highest AUC when detecting post-treatment composite 
clinical outcome of heavy or lower risk (AUC = 0.833) and had the lowest AUC when 
detecting 2+ level change in WHO risk level since baseline (calculated via drinks per 
drinking day (DDD); AUC = 0.511). For 12-month follow-up consumption outcomes, the 
BSI total score had the highest AUC when detecting the composite clinical outcome of 
heavy or lower risk (AUC = 0.708) and the lowest AUC when detecting 12-month 
abstinence (AUC = 0.545). 
 All post-treatment BSI subscales, representing the 9 factors of the BSI, adequately 
detected at least 1 of 15 post-treatment consumption outcomes. The Depression factor 
adequately detected 8 out of 15 post-treatment outcomes and 1 of 11 12-month follow-up 
outcomes. The Interpersonal Sensitivity factor adequately detected 8 out of 15 post-
treatment outcomes but 0 of 11 12-month follow-up outcomes. The Anxiety factor 
adequately detected 7 out of 15 post-treatment outcomes and 1 of 11 12-month follow-up 
outcomes. The Obsessive-Compulsive factor adequately detected 5 of 15 post-treatment 
outcomes and 1 of 11 12-month follow-up outcomes. The Psychoticism factor adequately 
detected 4 of 15 post-treatment outcomes and 1 of 11 12-month follow-up outcomes. The 
Somatization factor adequately detected 4 of 15 post-treatment outcomes but 0 of 11 12-
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month follow-up outcomes (AUC’s > 0.650). The Hostility factor adequately detected 3 
of 15 post-treatment outcomes and 1 of 11 12-month follow-up outcomes. The Paranoia 
symptom subscale adequately detected 1 of 15 post-treatment outcomes and 1 of 11 12-
month follow-up outcomes. Finally, the Phobic Anxiety factor adequately detected only 1 
of 15 post-treatment outcomes and none of the 12-month follow-up outcomes. Every BSI 
subscale had the highest AUC when detecting post-treatment and 12-month follow-up 
composite clinical outcome of heavy or lower risk (AUC’s = 0.713 to 0.833 post-
treatment; AUC’s = 0.638 to 0.706 12-month follow-up). Further, six of the nine 
subscales had the lowest AUC’s when detecting 1+ level change in WHO risk level since 
baseline (calculated via drinks per day (DPD); AUC’s = 0.529 to 0.568). For 12-month 
outcomes, eight of the nine subscales had the lowest AUC’s when detecting abstinence 
(AUC’s = 0.508 to 0.557); only the Psychoticism symptoms subscale had the lowest 
AUC when detecting 12-month WHO risk level of moderate or lower (calculated via 
drinks per drinking day (DDD); AUC = 0.523). As reported in Appendix A, many of the 
items on the BSI yielded AUC’s > 0.650 at post-treatment and the 12-month follow-up. 
 Beck Depression Inventory. The majority of published studies report that the 
BDI is comprised of 2 or 3 factors; therefore, it was unsurprising that both 2- and 3-factor 
models fit well in the MATCH data (2-factor model: RMSEA = 0.030 (90% CI: 0.025-
0.035); CFI = 0.978; TLI = 0.975; 3-factor model: RMSEA = 0.027 (90% CI: 0.021-
0.032); CFI = 0.982; TLI = 0.980). Further, both the 2- and the 3-factor models sustained 
comparable levels of fit through strong invariance testing between baseline and post-
treatment timepoints. The 2-factor model yielded good fit through constraints of 
thresholds to equivalence between timepoints (RMSEA = 0.019 (90% CI: 0.017-0.021); 
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CFI = 0.968; TLI = 0.969) as did the 3-factor model (RMSEA = 0.019 (90% CI: 0.017-
0.021); CFI = 0.970; TLI = 0.971; see Table 7). Similarly, internal consistency was good 
for the overall BDI (α = 0.889) as well as each factor, with the sole exception of the 
Somatic factor in the 3-factor model (see Table 8): 2-factor Cognitive-Affective factor α 
= 0.848, 2-factor Somatic factor α = 0.771, 3-factor Negative Attitudes factor α = 0.859, 
3-factor Performance Impairment factor α = 0.739, 3-factor Somatic factor α = 0.478. 
The convergent validity results for the total BDI were also good; the BDI was 
significantly negatively correlated with psychosocial functioning (PFI; r = -0.380, p < 
0.001) and employment status (ESI employment item; r = -0.150, p < 0.001).  
 As detailed in Table 10, ROC curve analyses indicated the BDI more strongly 
detected 12-month follow-up outcomes (4 of 11 outcomes were detected at AUC > 0.650) 
than post-treatment outcomes (2 of 15 outcomes were detected at AUC > 0.650). The 
total BDI summary score was had the highest AUC values detecting post-treatment and 
12-month composite clinical outcome of heavy or lower risk (AUC = 0.658; AUC = 
0.681) and the lowest AUCs when detecting 2+ change in WHO risk level since baseline 
(computed via DPD; AUC = 0.555) and 12-month abstinence (AUC = 0.596). The same 
patterns were observed for all factors upheld via CFA and invariance testing (2-factor 
Cognitive-Affective factor, 2-factor Somatic factor; 3-factor Negative Attitudes factor, 3-
factor Performance Impairment factor, 3-factor Somatic factor). For the 2-factor solution, 
the Cognitive-Affective factor and Somatic factor each adequately detected 3 of 15 post-
treatment outcomes, and 0 of 11 12-month outcomes. The 3-factor solution, the Negative 
Affect factor adequately detected 8 of 15 post-treatment outcomes and 0 of 11 12-month 
follow-up outcomes; the Performance Impairment factor and the Somatic factor each 
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adequately detected 2 of 15 post-treatment outcomes and 0 of 11 12-month follow-up 
outcomes. As reported in Appendix A, many of the items on the BDI yielded AUC’s > 
0.650 at post-treatment and the 12-month follow-up. 
 World Health Organization Quality of Life. The WHOQOL-BREF has been 
found to have a higher-order factor structure in previous publications (Skevington et al., 
2004). Although one item was omitted from the COMBINE Study administration, this 
higher-order factor structure was acceptably upheld in COMBINE via CFA (replication 
half fit indices: RMSEA = 0.050 (90% CI: 0.045, 0.055); CFI = 0.942; TLI = 0.932). 
Although other factor structures have been published in other datasets (e.g., Yao & Wu, 
2005), several previously published factor structures were tested in COMBINE with no 
one factor structure fitting substantially better than others. Accordingly, invariance 
testing was continued with the most widely-cited factor structure that made the most 
conceptual sense: the higher-order factor structure described by Skevington et al. (2004). 
Higher-order factor invariance testing was completed as described above with very little 
change to any of the fit indices. The least constrained level of invariance testing fit 
acceptably well across baseline and week 26 timepoints (RMSEA = 0.037 (90% CI: 
0.035, 0.038); CFI = 0.921; TLI = 0.916) as did the highest level of constraints possible 
for this measure (strong invariance: RMSEA = 0.037 (90% CI: 0.036, 0.039); CFI = 
0.926; TLI = 0.930). Further, the overall WHOQOL-BREF as well as the subscale factors 
had good to excellent internal consistency reliability, as indicated in Table 8 (α = 0.901 
for the overall measure; Physical Health α = 0.798, Psychological Health α = 0.770, 
Social Relationships α = 0.718, Environment α = 0.812). Similarly, the WHOQOL-BREF 
had good convergent validity and was significantly (p’s < 0.001), negatively correlated to 
36 
 
 
both alcohol-related consequences (DrInC; r = -0.456) and psychological symptoms 
(BSI; r = -0.698) as hypothesized.  
 Although not accounted for in the overall results summary (Table 6) because 
WHOQOL-BREF data were collected after the week 16 post-treatment timepoint, ROC 
curve analyses indicated that the week 26 WHOQOL-BREF data were adequately able to 
detect 12-month follow-up consumption outcomes (presented in Table 11). The total 
WHOQOL-BREF score adequately detected 4 of 11 consumption outcomes. The total 
WHOQOL-BREF summary score had the highest AUC when detecting 12-month 
composite clinical outcome of heavy or lower risk (AUC = 0.715) and had the lowest 
AUC when detecting 12-month abstinence (AUC = 0.508). The same pattern was 
observed for each of the 4 subscales of the WHOQOL-BREF that were upheld via CFA 
and invariance testing: 12-month composite clinical outcome of heavy or lower risk was 
the outcome with the highest AUC and 12-month abstinence was the outcome with the 
lowest AUC. The Physical Health, Social, and Environment subscales each only 
adequately detected 12-month composite clinical outcome of heavy or lower risk (AUC’s 
= 0.698, 0.691, 0.653). However, the Psychological Health subscale adequately detected 
12-month WHO risk moderate or lower risk (calculated via DDD and DPD; AUC’s = 
0.652, 0.659), 12-month composite clinical outcome of moderate or lower risk (AUC = 
0.665), and 12-month composite clinical outcome of heavy or lower risk (AUC = 0.704). 
As reported in Appendix A, several individual items of the WHOQOL-BREF adequately 
detected 12-month outcomes. 
Measures with Mixed Results 
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 Obsessive-Compulsive Drinking Scale. The Obsessive-Compulsive Drinking 
Scale (OCDS) has been conceptualized as a measure of alcohol craving, but publications 
have differed in their conceptualizations of factors comprising the OCDS. 
Unsurprisingly, multiple steps were taken to test various factor models. First, a 2-factor 
solution was tested based on the original conceptualization of the OCDS, which has been 
replicated in other studies (Ansseau et al., 2000; Anton 2000; Cordero, Solis, Cordero, 
Torruco, & Cruz-Fuentes, 2009). However, model fit was poor in the COMBINE data, 
and the model was not tested in the replication half of the sample (RMSEA = 0.109 (90% 
CI: 0.102-0.117); CFI = 0.852; TLI = 0.823). Model fit was similarly poor for alternative 
2-, 3-, and 4-factor models that were based on other published findings (see Table 7). 
Consequently, EFA was combined with conceptual interpretation of the items to generate 
a new 4-factor model that differs slightly from other studies. These 4-factors are 
consistent with a conceptualization of the OCDS as measuring: frequency of craving 
thoughts (“Factor 1”), craving interference with activities (“Factor 2”), distress of the 
craving (“Factor 3”), and controllability of craving (“Factor 4”). Notably, the two items 
of the OCDS that assess for alcohol consumption directly were omitted from the final 
factor model due to their poor contribution to the factor structures tested and per previous 
findings (Anton, 2000). This 4-factor model provided acceptable fit to baseline data in 
COMBINE (replication half sample: RMSEA = 0.072 (90% CI: 0.062-0.082); CFI = 
0.968; TLI = 0.596). Measurement invariance testing of this new 4-factor model yielded 
adequate fit statistics through strong invariance (see Table 7; RMSEA = 0.076 (90% CI: 
0.062, 0.082); CFI = 0.910; TLI = 0.912). However, fit substantially worsened between 
metric and strong invariance (i.e., when adding the constraint of equality of thresholds), 
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which may reflect measurement non-invariance at the threshold level. Attempts to 
establish partial strong invariance were unsuccessful and yielded consistently inadequate 
model fit. 
 Despite the potential non-invariance of the OCDS at the strong invariance level, 
the OCDS did have other psychometric strengths in COMBINE. The internal consistency 
was strong for the total OCDS score (α = 0.852) and convergent validity results yielded 
significant bivariate correlations in all Form 90 consumption variables, as predicted: PDA 
(r = -0.103, p < 0.001), PHDD (r = 0.202, p < 0.001), change in WHO risk level since 
baseline (as calculated with DDD: (r = 0.288, p < 0.001)), DPD (r = 0.305, p < 0.001), 
DDD (r = 0.360, p < 0.001 and MXD (r = 0.320, p < 0.001).  
 Moreover, the total summary score of the OCDS strongly detected all post-
treatment and 12-month follow-up consumption outcomes (presented in Table 12). Area 
under the curve (AUC) values for detecting post-treatment outcomes ranged from 0.686 
to 0.934; those for 12-month outcomes ranged from 0.690 and 0.756. For post-treatment 
outcomes, the OCDS total summary score yielded the highest AUC for post-treatment 
composite clinical outcome of heavy or lower risk and was lowest AUC for 1+ level 
change in WHO risk level since baseline (computed via DDD). For 12-month follow-up 
outcomes, the OCDS total summary score yielded highest AUC for composite clinical 
outcome of moderate or lower risk and lowest AUC for WHO moderate or lower risk 
(calculated via DDD).  
 The 4 factors that were partially supported per adequate CFA results and partial 
invariance testing yielded several promising ROC curve results (AUC’s > 0.650). Factors 
1 and 2 both adequately detected 11 of 15 post-treatment outcomes (all but 1+ and 2+ 
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risk level changes in WHO risk levels since baseline as computed via DDD and DPD): 
AUC’s ranged from 0.589 to 0.782 for Factor 1 and 0.614 to 0.871 for Factor 2. Factors 1 
and 2 also adequately detected 12-month composite clinical outcome of heavy or lower 
risk (AUC’s = 0.668 and 0.672) and had lowest AUCs when detecting 12-month 
abstinence (AUC’s = 0.604 and 0.566). Factors 3 and 4 performed even better than 
Factors 1 and 2. Factor 3 adequately detected 13 out of 15 post-treatment outcomes; 
AUC’s ranged between 0.631 (2+ change in WHO risk level since baseline, calculated 
via DPD) and 0.877 (composite clinical outcome of heavy or lower risk). Factor 3 also 
adequately detected 7 of 11 12-month outcomes; AUC’s ranged from 0.641 (WHO 
moderate or lower risk, calculated via max drinks (MXD) to 0.716 (composite clinical 
outcome of heavy or lower risk). Factor 4 performed superior and adequately detected 15 
of 15 and 11 of 11 post-treatment (AUC’s ranged from 0.676 to 0.912) and 12-month 
outcomes (AUC’s ranged from 0.682 to 0.742). For post-treatment outcomes, Factor 4 
had highest AUC for composite clinical outcome of heavy or lower risk and lowest AUC 
for 1+ change in WHO risk level since baseline (as calculated via DDD). For 12-month 
follow-up outcomes, Factor 4 had highest AUC for composite clinical outcome of 
moderate or lower risk and lowest AUC for WHO moderate or lower risk level 
(calculated via DDD). As reported in Appendix A, many of the items on the OCDS 
yielded AUC’s > 0.650 at post-treatment and the 12-month follow-up.  
Drinker Inventory of Consequences. Similar to the OCDS, the factor structure 
of the DrInC has been explored in numerous prior studies, including several publications 
on the 15-item abbreviated version, the Short Inventory of Problems (SIP; e.g., 
Forcehimes, Tonigan, Miller, Kenna, & Baer, 2007; Kiluk, Dreifuss, Weiss, 
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Morgenstern, & Carroll, 2012). Accordingly, a number of factor structures were tested in 
COMBINE and MATCH via CFA for the DrInC as well as the SIP (see Table 7 for fit 
statistics). The only factor structure tested in the present study that yielded adequate fit in 
both COMBINE and MATCH and was invariant beyond configural invariance was a 3-
factor solution created in the present study based on a conceptualization of the DrInC as 
consisting of alcohol related consequences that occur at different frequencies (e.g., 
consequences that occur commonly, such as hangovers; consequences that occur 
moderately commonly; and rare consequences). As detailed in Table 7, this 3-factor 
solution fit adequately at baseline in both COMBINE and MATCH (COMBINE: 
RMSEA = 0.041 (90% CI: 0.038, 0.043); CFI = 0.920; TLI = 0.916; MATCH: RMSEA 
= 0.040 (90% CI: 0.038, 0.042); CFI = 0.908; TLI = 0.904) and fit improved as additional 
constraints were added through constraining thresholds to equivalence across time 
(COMBINE: RMSEA = 0.024 (90% CI: 0.023, 0.025); CFI = 0.951; TLI = 0.952; 
MATCH: RMSEA = 0.018 (90% CI: 0.017, 0.019); CFI = 0.941; TLI = 0.942). 
Similarly, the total DrInC and the 3 factors all had strong internal consistency in 
COMBINE and MATCH. As described in Table 8, total DrInC in COMBINE and 
MATCH had α = 0.937 and α = 0.938, respectively. The 3-factor subscales in COMBINE 
and MATCH were: Common Consequences α = 0.855, α = 0.833; Moderately Common 
Consequences α = 0.905, α = 0.905; and Rare Consequences α = 0.808, α = 0.830. 
 Bivariate correlations were significant and in the expected direction for Form 90 
variables (p < .01 in both COMBINE and MATCH). Other variables were also 
significantly correlated in the hypothesized directions in COMBINE: OCDS r = 0.519 (p 
< 0.001), AASE r = 0.153 (p < 0.001), WHOQOL-BREF r = -0.456 (p < 0.001), SF-12 r 
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= -0.486 (p < 0.001), recoded employment status r = -0.225 (p < 0.001) and income r = -
0.233 (p < 0.001). In MATCH, the DrInC also significantly correlated with other 
hypothesized measures as predicted: PFI r = -0.479 (p < 0.001) and recoded employment 
status r = -0.164 (p < 0.001). However, the DrInC had poor convergent validity in 
MATCH with temptation to drink (r = -0.060, p < 0.05) and AA involvement (AAI; r = 
0.336, p < .001). These inconsistent psychometrics across COMBINE and MATCH may 
be due to the inconsistent administration in MATCH to individuals who had been 100% 
abstinent during the follow-up window. 
 For the DrInC summary ROC curve analyses, all DrInC summary AUC values > 
0.650 in COMBINE for both timepoints (post-treatment AUC’s = 0.677-0.944; 12-month 
follow-up AUC’s = 0.684-0.736; see Table 13). Further, the first two factors adequately 
detected all post-treatment and 12-month follow-up outcomes: Common Consequence 
Factor post-treatment AUC’s = 0.677-0.939, 12-month AUC’s = 0.671-0.719; 
Moderately Common Consequences Factor post-treatment AUC’s = 0.663-0.939, 12-
month AUC’s = 0.659-0.715. The Rare Consequences Factor adequately detected 14 of 
15 post-treatment outcomes (AUC’s = 0.642-0.917) and 10 of 11 12-month AUC’s = 
0.645-0.699). The DrInC total score and each of the 3 factors had the highest AUC’s for 
composite clinical outcome of heavy or lower risk and the lowest AUC’s for 2+ level 
change in WHO risk level since baseline (computed via DPD). For 12-month follow-up 
outcomes, DrInC total score and each of the 3 factors all had the highest AUC’s for 
composite clinical outcome of moderate or lower risk and the lowest AUC’s for 
abstinence. As reported in Appendix A, many of the items on the DrInC yielded AUC’s > 
0.650 at post-treatment and the 12-month follow-up. 
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 In MATCH, the total DrInC summary adequately detected 9 of 15 post-treatment 
outcomes (AUC’s = 0.493-0.886) but failed to adequately detect any 12-month outcomes 
(AUC’s = 0.424-0.590; see Table 14). Similarly, each of the 3-factors adequately 
detected 8 of 15 post-treatment outcomes but failed to detect any 12-month follow-up 
outcomes: Common Consequence Factor post-treatment outcomes AUC’s = 0.508-0.850; 
Moderately Common Consequences Factor post-treatment outcomes AUC’s = 0.495-
0.879; Rare Consequences Factor post-treatment outcomes AUC’s = 0.513-0.876. Similar 
with the COMBINE study results, the DrInC total score and each of the 3 factors all had 
the highest AUC’s for composite clinical outcome of moderate or lower risk and the 
lowest AUC’s for 2+ level change in WHO risk level since baseline (computed via DPD). 
For 12-month follow-up outcomes, DrInC total score and each of the 3 factors all had the 
highest AUC’s for composite clinical outcome of moderate or lower risk and the lowest 
AUC’s for abstinence. As reported in Appendix A, many of the items on the DrInC 
yielded AUC’s > 0.650 at post-treatment and the 12-month follow-up in Project 
MATCH. 
Measures with Poorer Results  
 Spielberger State-Trait Inventory. The two factors (Temperament and 
Reaction) that have been previously described in the literature (Forgays et al., 1997) 
provided poor fit to the data in Project MATCH via CFA (split half 1 sample: RMSEA = 
0.116 (90% CI: 0.109-0.122); CFI – 0.902; TLI = 0.884). However, Forgays and 
colleagues (1997) also described the SSTI in terms of 7 subscales. The items 
administered in MATCH consisted of 4 of those 7 subscales; this 4-factor model 
provided excellent fit via CFA in MATCH data (replication half sample: RMSEA = 
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0.056 (90% CI: 0.048-0.064); CFI – 0.976; TLI = 0.969). Because the SSTI was only 
administered at baseline in Project MATCH, measurement invariance across time was not 
tested in the present study for this 4-factor solution. Factor analysis results are detailed in 
Table 7. Further, the overall SSTI scale had excellent internal consistency (α = 0.887) and 
all but one of these 4 factors had good internal consistency: “Factor 1” α = 0.746, “Factor 
2” α = 0.865, “Factor 4” α = 0.496, and “Factor 6” α = 0.781 (as detailed in Table 8).  
 The SSTI performed inadequately in terms of both convergent validity and 
sensitivity/specificity. The SSTI was significantly correlated with the PFI as 
hypothesized (r = -0.200; p < 0.001) and the SSTI summary score using only the items in 
the CFA (r = -0.053, p < 0.05) but the full SSTI summary score was not significantly 
correlated with recoded employment status in MATCH (r = -0.051, p > 0.05). A bigger 
weakness of the SSTI was its poor sensitivity and specificity for detecting consumption 
outcomes. For the full SSTI and each of the 4 factors tested via CFA, AUC values were 
below the 0.650 cutoff for all consumption outcomes at both post-treatment and 12-
month follow-up (see Table 15). The total SSTI score (including all items administered in 
MATCH) had AUC values ranging from 0.503-0.577 and 0.499-0.559 for post-treatment 
and 12-month follow-up outcomes. Similarly, AUC values for the total SSTI score 
(including only the items from CFA) ranged from 0.504-0.575 and 0.501-0.561 for post-
treatment and 12-month follow-up outcomes. Both of these forms of the total SSTI score 
had highest AUC for post-treatment WHO moderate or lower risk (calculated via DPD) 
and 12-month composite clinical outcome of heavy or lower risk; the lowest AUC’s for 
both total SSTI scores were detecting 2+ level change in WHO risk level since baseline 
(calculated via DPD) and 12-month abstinence. No consistent pattern emerged for which 
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post-treatment and 12-month follow-up outcomes had consistently the highest or lowest 
AUC for the 4 factors that were upheld via CFA, but none of the 4 factors were able to 
adequately detect post-treatment or 12-month follow-up outcomes (AUC’s = 0.490-
0.576). 
 Health Survey (SF-12). The SF-12 yielded mixed and modest findings for 
construct validity, measurement invariance testing, and ROC curve analyses results but 
had promising internal consistency and convergent validity in COMBINE. Despite the 
substantial body of literature and conceptual sense supporting the SF-12 as comprised of 
2 factors (Physical Health and Psychological Health), CFA analyses indicated only an 
adequate fit of this model (RMSEA = 0.080 (90% CI: 0.071, 0.090); CFI = 0.951; TLI = 
0.939). Further, configural invariance was not upheld per fit indices that were outside a 
priori cutoff values and the configural invariance mode fit substantially poorer than the 
baseline CFA (RMSEA = 0.075 (90% CI: 0.072, 0.078); CFI = 0.854; TLI = 0.839). 
Additional levels of invariance were not tested per the above evidence of configural non-
invariance.  
 The SF-12 as administered in COMBINE had good internal consistency and 
convergent validity. Internal consistency was good for total SF-12 (α = 0.874) as well as 
both Physical (α = 0.805) and Psychological Health (α = 0.861) factors. Convergent 
validity was particularly strong. The total SF-12 score was highly, negatively correlated 
with both alcohol-related consequences (DrInC; r = -0.486, p < 0.001) and total 
psychiatry symptom severity (BSI; r = -0.688, p < 0.001). 
 ROC curve analyses results were mixed, as detailed in Table 16. The total SF-12 
summary score performed well for detecting consumption outcomes at post-treatment (8 
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of 15 outcomes were adequately detected, AUC’s = 0.577-0.836), performed poorly at 
detecting 12-month follow-up consumption outcomes (1 of 11 outcomes was adequately 
detected, AUC’s = 0.548-0.681). Similarly, the Physical Health and Psychological Health 
factors detected post-treatment consumption outcomes fairly well (4 of 15 and 9 of 15, 
respectively; AUC’s = 0.522-0.766 and 0.600-0.840) whereas the Physical Health factor 
failed to adequately detect any 12-month follow-up consumption outcomes (AUC’s = 
0.518-0.627) and the Psychological Health factor only adequately detected 1 of 11 
consumption outcomes for the 12-month follow-up (AUC’s = 0.561-0.693). The total 
summary score and each of the 2 factors all had highest AUC’s for post-treatment and 
12-month follow-up composite clinical outcome of heavy or lower risk. The total SF-12 
score and the Physical Health factor both had lowest AUC’s for 1+ level change in WHO 
risk level since baseline (calculated via DPD); the Psychological Health factor had lowest 
AUC for 2+ level change in WHO risk level since baseline (calculated via DPD). The 12-
month abstinence was the lowest AUC for total SF-12 and both factors. As reported in 
Appendix A, many of the items on the SF-12 yielded AUC’s > 0.650 at post-treatment. 
Only one item on the SF-12 (item 6A: “felt calm or peaceful”) yielded AUC’s > 0.650 in 
predicting the composite clinical outcome of heavy or lower risk at the 12-month follow-
up. 
 Psychosocial Functioning Inventory. The items of the PFI administered in 
MATCH are consistent with three of the factors in the original conceptualization of the 
PFI’s construction (Feragne et al., 1983). Those three factors are:  Subjective Role 
Performance, Overall Social Role Performance, and Housemate/Roommate Role. In 
CFA, results indicated this 3-factor model fit acceptably well and replicated in the second 
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split half sample (RMSEA = 0.052 (90% CI: 0.047, 0.057); CFI = 0.933; TLI = 0.923). 
However, model fit was substantially poorer in the configural invariance model (RMSEA 
= 0.042 (90% CI: 0.041, 0.044); CFI = 0.822; TLI = 0.811). Because CFI and TLI fit 
indices decreased below a priori cutoffs for adequate model fit, configural invariance fit 
was determined to be too inadequate to warrant further invariance testing. Accordingly, 
the 3-factor model of the items of the PFI administered in MATCH was non-invariant 
over baseline and post-treatment timepoints. These poor findings may be due to the fact 
that MATCH administered an abbreviated version of the PFI. 
 Despite these findings, the PFI performed reasonably well on internal consistency 
and convergent validity analyses. Except for the Housemate/Roommate role factor (α = 
0.531), internal consistency was good: total PFI α = 0.867, Subjective Role Performance 
factor α = 0.817, Overall Social Role Performance factor α = 0.818 (see Table 8). Further, 
the convergent validity results were all significant (p < 0.001) and in the expected 
direction. The PFI was significantly, negatively correlated with SSTI (r = -0.200) and 
BDI (r = -0.380).  
 The PFI performed poorly with respect to sensitivity/specificity and adequately 
detected only some consumption outcomes, as detailed in Table 17. Total PFI summary 
scores only adequately detected 4 of 15 post-treatment outcomes (AUC’s = 0.538-0.700) 
and failed to adequately detect any consumption outcomes at 12-month follow-up 
(AUC’s = 0.533-0.600). Since CFA results indicated an adequately-fitting 3-factor 
structure, these 3 factor summary scores were examined via ROC curve analyses, 
yielding very few positive results. The Subjective Role Performance factor failed to 
adequately detect any post-treatment (AUC’s = 0.522-0.644) or 12-month follow-up 
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outcomes (AUC’s = 0.517-0.582). The Overall Social Role Performance factor 
adequately detected only 1 of 15 post-treatment consumption outcomes (AUC’s = 0.520-
0.663) and the Housemate/Roommate Role factor only adequately detected 2 of 15 post-
treatment outcomes (AUC’s = 0.537-0.660). Neither the Overall Social Role Performance 
factor nor the Housemate/Roommate Role factor adequately detected any 12-month 
follow-up outcomes (AUC’s = 0.517-0.582, 0.531-0.585). There was no consistent 
pattern for which post-treatment or 12-month follow-up outcomes yielded highest AUC’s 
when detected by the PFI total summary score or any of the factors, but 2+ level change 
in WHO risk level since baseline (calculated via DPD) and 12-month abstinence were the 
lowest AUC’s for all 4 PFI variables. As reported in Appendix A, only 2 items 
adequately detected any consumption outcomes: Item 11 (spousal/mate overall role 
performance; Social Role Performance factor) and 19 (housemate/roommate overall role 
performance). 
 Alcohol-Abstinence Self-Efficacy Scale. The Alcohol-Abstinence Self-Efficacy 
Scale (AASE; DiClemente et al., 1994) was tested in both COMBINE and MATCH for 
the present study. Since the bulk of previous studies have found a 4-factor model in 
previous administrations of the AASE, this model was tested via CFA. This model 
provided an adequate fit in COMBINE (replication half fit indices: RMSEA = 0.050 
(90% CI: 0.048, 0.053); CFI = 0.919; TLI = 0.914), but failed to provide an adequate fit 
in the overall MATCH dataset (split half 1 sub-sample fit indices: RMSEA = 0.060 (90% 
CI: 0.058, 0.062); CFI = 0.866; TLI = 0.857). An additional CFA was conducted to 
examine the fit of this 4-factor model in each treatment arm (aftercare and outpatient) for 
three reasons: 1) known differences in participant characteristics in the treatment arms of 
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Project MATCH, 2) the fact that the previously published 4-factor model of the AASE fit 
acceptably well in COMBINE, and 3) that the present study aimed for measurement 
preservation rather than data-driven methodology that could limit generalizability of 
findings. As shown in Table 7, the model fit adequately in the outpatient treatment arm of 
MATCH (replication half fit indices: RMSEA = 0.050 (90% CI: 0.047, 0.053); CFI = 
0.931; TLI = 0.926). Moreover, this 4-factor model was invariant across time through 
strong invariance in both COMBINE and MATCH: COMBINE strong invariance 
RMSEA = 0.033 (90% CI: 0.032, 0.034); CFI = 0.953; TLI = 0.954; MATCH outpatient 
arm strong invariance RMSEA = 0.027 (90% CI: 0.026, 0.029); CFI = 0.917; TLI = 
0.914.  
 Despite the strong invariance across baseline and post-treatment timepoints that 
replicated in both COMBINE and MATCH, however, other properties of the AASE were 
less promising. As described in Table 8, internal consistency of the overall AASE was 
good (α = 0.752 in COMBINE; α = 0.841 in MATCH) but internal consistency of each of 
the 4 factors was sub-optimal in both COMBINE and MATCH (COMBINE, MATCH: 
Negative Affect factor α = 0.356, 0.557; Social/Positive factor α = 0.341, 0.460; Physical 
& Other Concern factor α = 0.162, 0.546; and Withdrawal & Urges factor α = 0.279, 
0.458). However, internal consistency is greatly influenced by the number of items 
contained in a measure or factor, so these low internal consistency reliability values may 
be because the AASE is a brief questionnaire.  
 More importantly, there were mixed findings for the convergent validity of the 
AASE. In COMBINE and MATCH, the AASE and its 4 factors were only significantly 
correlated with some of the Form 90 consumption variables and since the AASE purports 
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to measure craving and temptation to drink, one would expect all Form 90 consumption 
variables to be significantly correlated with the AASE. In COMBINE and MATCH, the 
total AASE correlations were: PDA r = -0.012 (p > 0.05) and r = -0.063 (p < 0.01); 
PHDD r = 0.011 (p > 0.05) and r = 0.062 (p < 0.05); DDD r = 0.079 (p < 0.01) and r = 
0.032 (p > 0.05); MXD r = 0.104 (p < 0.001) and r = 0.061 (p < 0.05); and DPD r = 
0.070 (p > 0.05) and r = 0.067 (p < 0.01). Bivariate correlations were similarly mixed for 
each of the 4 factors in COMBINE and MATCH. 
 Sensitivity/specificity of the AASE and the 4 subscales were all below the AUC > 
0.650 cutoff for all post-treatment and 12-month follow-up outcomes in both COMBINE 
and MATCH (detailed in Tables 18 and 19). This suggests the total AASE summary 
score and 4 factors are markedly poor at detecting concurrent and future consumption 
outcomes.  
 One potential exception to the poor sensitivity/specificity of the AASE in 
COMBINE and MATCH was the notably strong AUC values for the Temptation and 
Confidence subscales of the AASE. The summary scores of items in each of these 2 
categories of items (Confidence and Temptation) were examined in terms of their 
sensitivity/specificity (presented in Tables 18 and 19). In the COMBINE Study, the 
summary of Confidence items and summary of Temptation items each adequately 
detected all concurrent (AUC’s = 0.674-0.879, 0.669-0.858) and 12-month follow-up 
consumption outcomes (AUC’s = 0.664-0.732, 0.690-0.734). In Project MATCH, the 
summary of Confidence items adequately detected 13 of 15 post-treatment (AUC’s = 
0.611-0.733) and 10 of 11 12-month follow-up consumption outcomes (AUC’s = 0.649-
0.690). Similarly, the summary of Temptation items in MATCH adequately detected 11 
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of 15 post-treatment (AUC’s = 0.537-0.655) and all 11 12-month follow-up consumption 
outcomes (AUC’s = 0.655-0.712). No consistent pattern emerged for which post-
treatment or 12-month consumption outcomes yielded highest AUC’s for the AASE 
Confidence or Temptation subscales across COMBINE and MATCH, except that 12-
month composite clinical outcome of moderate or lower risk had the highest AUC’s for 
both Confidence and Temptation subscales in both COMBINE and MATCH. 
 Consideration was given to these two summary scores via preliminary CFA 
testing of the AASE as a 2-factor solution; however, model fit was inadequate and not 
explored further (COMBINE split half 1 fit indices: RMSEA = 0.068 (90% CI: 0.065, 
0.070); CFI = 0.897; TLI = 0.889; MATCH full sample split half 1 fit indices: RMSEA = 
0.053 (90% CI: 0.050, 0.055); CFI = 0.856; TLI = 0.848). Future research should 
investigate these two summary scores further given their strong sensitivity/specificity for 
detecting consumption outcomes. 
The Addiction Severity Index. Because the original ASI was not administered in 
Project MATCH, numerous strategies were employed to identify a factor model to test 
via CFA (detailed in Table 7). First, a 3-factor model based on the structure described by 
McLellan and colleagues (1992) was tested and failed to converge. Then, that model was 
altered to account for the restricted distributions of data in MATCH and the high 
intercorrelations between items; this model also failed to converge. Next, item question 
content and data distributions were explored closely to identify overlapping question 
content and to identify response categories that could be collapsed to mitigate potential 
data sparseness. No alternative factor structures emerged successfully from these 
procedures.  
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 The total ASI score, as administered in Project MATCH, also performed poorly 
from other psychometric perspectives. The total ASI internal consistency was poor (α = 
0.327), which is unsurprising given the content of the items differed substantially from 
one category (e.g., legal problems) to the next (e.g., psychological problems). Convergent 
validity results yielded mixed findings whereby the total ASI score was significantly 
correlated with some but not all Form 90 consumption variables. Specifically, the ASI 
was significantly correlated with DPD and MXD (r = 0.068, p < 0.01; r = 0.064, p < 
0.01), but these low correlation values may have been significant due to the large sample 
size of Project MATCH. All other convergent validity results were non-significant, 
including other consumption variables (e.g., PDA, PHDD), temptation items, PFI, ESI, 
and Alcoholic Anonymous Involvement (p’s < 0.05). Finally, the ASI failed to detect any 
post-treatment or 12-month follow-up consumption outcomes over the AUC > 0.650 
level. Post-treatment consumption outcomes were detected at AUC values between 0.494 
and 0.612; 12-month follow-up consumption outcomes were detected at AUC values 
between 0.492 and 0.544 (detailed in Table 20). Accordingly, the ASI as administered in 
Project MATCH had poor construct validity, internal consistency, convergent validity, 
and sensitivity/specificity to detect consumption outcomes.  
ROC Curve Analyses of Consumption Variables 
 Results indicated that both PDA and PHDD were largely adequately 
sensitive/specific to detect consumption-based outcomes per the AUC > 0.65 a priori 
cutoff (presented in Table 21). In the COMBINE Study, post-treatment outcome AUC 
values for PDA and PHDD ranged from 0.670 to 0.988. AUC values for both PDA and 
PHDD were largest for detecting specific WHO risk levels and composite clinical scores 
52 
 
 
and lowest for detecting changes in WHO risk level since baseline timepoint. These 
overall patterns were replicated in the post-treatment MATCH data (month 3) where 
AUC values ranged from 0.610 to 0.994 with specific WHO risk levels and composite 
clinical scores had highest AUC’s and changes in WHO risk had lowest AUC’s. 
 For ROC curve analyses of post-treatment PDA and PHDD detecting 12-month 
follow-up consumption outcomes, all AUC values were lower than for those of congruent 
timepoints in COMBINE and MATCH (described above). AUC values for PDA and 
PHDD detecting 12-month follow-up consumption outcomes ranged from 0.682 to 0.798 
in COMBINE data and 0.668 to 0.754 in MATCH. Given the small range in AUC values, 
no clear pattern emerged as to which 12-month follow-up outcomes were most or least 
easily detected via PDA or PHDD in COMBINE or MATCH. 
Discussion 
 The current study was a secondary analysis of data from the two largest 
randomized clinical trials for alcohol use disorder (AUD) ever conducted (the COMBINE 
Study (Anton et al., 2006) and Project MATCH (Project MATCH Research Group, 
1996)) to examine the measurement stability, internal consistency reliability, construct 
and convergent validity, sensitivity, and specificity of numerous non-consumption 
outcome measures. These analyses constitute some of the most broad and rigorous 
analyses ever conducted with these measures of non-consumption constructs. Such 
extensive analyses of measures administered in the COMBINE Study and Project 
MATCH have highlighted several promising measures for use in future research. 
Although no one construct performed consistency well across all measures tested, 
individual measures stood out as viable options for measuring a variety of constructs. The 
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Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), and the brief World 
Health Organization Quality of Life measure (WHOQOL-BREF) as administered in 
COMBINE or MATCH demonstrated strong viability for future use as measures of 
psychological health and quality of life. Importantly, these three measures had good 
construct validity and were invariant across time, which supports their use for examining 
pre- to post-treatment changes in these constructs. Moreover, these three measures 
adequately detected at least some consumption outcomes, as illustrated via ROC curve 
analyses. These administrations of the BSI, BDI, and WHOQOL-BREF in COMBINE 
and MATCH also had good convergent validity and internal consistency reliability. 
 Other measures administered in COMBINE and MATCH yielded mixed findings. 
Measures that showed the most promise for use in AUD treatment research were the 
Obsessive-Compulsive Drinking Scale (OCDS) and the Drinker Inventory of 
Consequences (DrInC) due to their having evidence for at least partial measurement 
invariance across time and at least some evidence for their sensitivity/specificity to detect 
consumption outcomes. Since the main goal of the present study was to identify measures 
that may be viable for use in examining pre- and post-treatment changes for AUD 
treatment research, more credence was given to these results (i.e., invariance, 
sensitivity/specificity) as more directly related to the research question. As such, the 
OCDS and DrInC were shown to have the most promise and minor refinement may 
further improve their suitability for use in AUD treatment research. 
 Findings from the present study also highlighted a few measures that warrant 
further investigation and refinement for use in AUD treatment research. The Spielberger 
State-Trait Inventory (SSTI) had strong internal consistency and construct validity, but 
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more research is needed to improve the convergent validity and sensitivity/specificity. 
The Short Form Health Survey (SF-12) and the Psychosocial Functioning Inventory (PFI) 
each had acceptable convergent validity, strong internal consistency, strong convergent 
validity, and had acceptable sensitivity/specificity but more research is needed to 
establish more robust factor structures that will be invariant across time. The Alcohol 
Abstinence Self-Efficacy Scale (AASE) had acceptable construct validity and was 
invariant across time in both COMBINE and MATCH, had acceptable internal 
consistency, and had acceptable convergent validity. However, the AASE had poor 
sensitivity/specificity in both COMBINE and MATCH for detecting all post-treatment 
and 12-month follow-up consumption outcomes. However, ROC curve results from the 
present study highlighted the good sensitivity/specificity of the AASE Confidence and 
Temptation subscales and future research may be able to use these two subscales rather 
than the total AASE score to examine pre- and post-treatment differences in self-efficacy 
and temptation to drink. 
 Only the Addiction Severity Index (ASI), as administered in MATCH, failed to 
perform adequately across all psychometric analyses. Data distributions appeared to be 
driving the poor performance of the ASI, which likely indicates that aggregating data 
from the ASI items is counter to its utility. The content of individual items in the ASI 
may still be useful in clinical settings and in research from an individual participant 
perspective. For instance, it may be interesting and informative clinically and in research 
to know the number of times an individual client or participant has experienced each of 
the psychiatric symptoms or engaged in specific illegal activities that are each assessed 
via the ASI. However, summarizing items and averaging scores across clients based on 
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the published ASI factor structure does not appear to be advisable based on the present 
findings. These findings are consistent with previously published cautions against the 
ASI (DeJong et al., 1995). 
 The limitations highlighted by the ASI and the mixed results for many other 
measures administered in the COMBINE Study and Project MATCH highlight an 
important gap in current AUD treatment research: a need for more rigorously developed 
assessment tools. Although the COMBINE Study and Project MATCH utilized the state 
of the science assessment tools, many of the measures that were used in these studies 
continue to be used in current research despite a lack of clear psychometric strength. The 
present results highlight that many non-consumption measures are viable or promising 
for use in future research; however, non-consumption measures could be even stronger 
psychometrically. First, more stringent, empirically-driven methodologies should be used 
to develop measures whereas many currently used measures were developed solely by 
researchers. Ideally, measurement development is a multiphase process where a measure 
is developed iteratively based on data from multiple sources, including experts, 
researchers, and study populations themselves (e.g., the Delphi process; Polit & Hungler, 
1999). Second, more extensive and appropriate psychometric analyses should be 
conducted for measures before they become widely used. Many of the previously 
published studies of measures’ psychometric appropriateness of use in AUD treatment 
research stemmed from internal consistency and principal components analyses (PCA). 
However, many psychometricians would argue that internal consistency is not the sole, 
nor best, metric for evaluating reliability. Further, PCA is ill-suited for examining factor 
structure and construct validity (e.g., Floyd & Widaman, 1995). Instead, other forms of 
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reliability and validity testing could be used in initial measurement development (e.g., 
test-retest reliability, confirmatory factor analyses; DeVellis, 2012). Unsurprisingly, the 
measures that performed the best in the present study (the Brief Symptom Inventory, 
Beck Depression Inventory, and the World Health Organization Quality of Life, Brief 
version) were three of the more rigorously developed and evaluated measures utilized in 
the COMBINE Study and Project MATCH. With more rigorously developed measures, it 
is entirely possible that non-consumption variables would yield consistently strong results 
and AUD researchers would no longer need to use consumption variables as “surrogates” 
for these more clinically meaningful, non-consumption constructs. 
 With respect to consumption outcomes being necessary as “surrogates” for non-
consumption outcomes, it is important to note that the present study found evidence to 
contradict this assumption. Many non-consumption variables were not exceptionally bad 
at detecting consumption outcomes and numerous non-consumption measures had large 
effect sizes, even when aggregated across the overall samples in the COMBINE Study 
and Project MATCH. For example, the Drinker Inventory of Consequences (DrInC) and 
the 3 factors identified in the present study, the Obsessive-Compulsive Drinking Scale 
(OCDS) and the 4 factors used in the present study, and the Confidence and Temptation 
subscales of the Alcohol-Abstinence Self-Efficacy (AASE) all had good 
sensitivity/specificity for detecting consumption outcomes and demonstrated large effect 
sizes, especially in the COMBINE Study. These findings are despite the long-standing 
claim that consumption variables must be used as a “surrogate” for more clinically 
meaningful non-consumption outcomes due to the inability of non-consumption 
outcomes to be sensitive to change (e.g., FDA, 2015, p. 2). Although area under the curve 
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(AUC) values were generally higher for consumption variables detecting consumption 
outcomes than those for non-consumption variables, several non-consumption variables 
performed adequately and several non-consumption variables had AUC values 
comparable to those for consumption variables. For example, the 3-factor model of the 
DrInC described in the present study yielded AUC values similar to those of consumption 
variables, especially in the COMBINE Study. Some AUC values for the DrInC subscales 
in COMBINE were as high as 0.939, which corresponds to an almost perfect 
detection/discrimination ability. The DrInC corresponds to alcohol-related consequences 
that are far more aligned with diagnostic criteria for AUD than consumption variables, 
which have never been part of diagnostic criteria used by the American Psychiatric 
Association.  
 Another interesting finding was a general pattern of which consumption outcomes 
were adequately detected or not detected by non-consumption variables. The majority of 
non-consumption variables had their highest AUC values for composite clinical outcome 
scores (especially the heavy drinking/problems or lower risk level) for both post-
treatment and 12-month follow-up timelines. The post-treatment outcome that yielded the 
lowest AUC’s by the majority of non-consumption variables was the 2+ levels of change 
in WHO risk level from baseline. The 12-month consumption outcome that yielded the 
lowest AUC’s by many non-consumption variables was 12-month abstinence. These 
patterns were largely consistent with consumption variable ROC curve results (PDA and 
PHDD ROC curve analyses), suggesting that post-treatment WHO Risk Level changes 
from baseline and 12-month abstinence may not be the best outcomes to use in evaluating 
treatment efficacy given the difficulty of accurately detecting these outcomes. Instead, 
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the present findings suggest future research evaluate treatment efficacy based on the most 
readily detected outcome: composite clinical score. The composite clinical scores that 
systematically yielded the highest AUC’s for both consumption and non-consumption 
variables were moderate or lower risk and heavy drinking/problems or lower risk. 
 Recent studies have suggested the shift in WHO risk level, as a consumption 
based outcome, may provide a viable alternative to abstinence and percent subjects with 
no heavy drinking days as endpoints for alcohol clinical trials (Hasin et al., in press; 
Witkiewitz et al., 2017). In the current study, the method of calculation of the WHO risk 
level variables impacted how those consumption outcomes were detected by both non-
consumption variables as well as PDA and PHDD. Specifically, WHO risk levels 
calculated via drinks per drinking day (DDD), maximum number of drinks consumed in 
the 90-day window (MXD) and drinks per day in the assessment window (averaged 
across drinking and abstinent days; DPD) yielded inconsistent AUC values across 
variables. For some variables, AUC values were relatively equitable across DDD, MXD, 
and DPD calculations. However, for some variables such as the Beck Depression 
Inventory scores and Drinker Inventory of Consequences (in Project MATCH 
especially), AUC values varied substantively between DDD, MXD, and DPD 
calculations of WHO risk levels. These findings suggest more research is needed to 
establish which calculation method (DDD, MXD, or DPD) is most stable across various 
conditions. Further, the fact that sensitivity/specificity can vary so meaningfully in 
consumption outcomes is another indication that consumption variables may not be as 
dependable as previously assumed by AUD treatment researchers.  
Limitations 
59 
 
 
 The primary limitation of the present study was that findings are specific to 
administration of the measures in the COMBINE Study and Project MATCH. Many of 
the measures examined in the present study were abbreviated versions of the full 
measures. For example, the WHOQOL-BREF as administered in COMBINE was one 
item short of the full WHOQOL-BREF. It is unclear why one item was omitted in the 
COMBINE Study, though it seems likely the item was omitted erroneously since it is the 
last item of the measure. However, the WHOQOL-BREF as administered in COMBINE 
performed well despite this missing item. Other abbreviated measures did not perform so 
well. Notably, the ASI, SSTI, and PFI were all abbreviated versions of these measures, 
which may or may not account for the poor results found for these measures in MATCH 
compared to previous studies (e.g., Feragne, 1983; McLellan et al., 1980). The results 
from the present study provide evidence that abbreviated versions of measures should be 
thoroughly explored psychometrically prior to their use in AUD treatment research. 
 The present findings are also limited by the availability of certain measures at 
different assessment periods. The post-treatment WHOQOL-BREF in COMBINE was 
administered at week 26, which fails to map on to the week 16 data that were examined 
for other measures. This inconsistency restricted the examination of post-treatment ROC 
curves for WHOQOL-BREF. Moreover, baseline data were only available for the SSTI, 
which prevented the examination of measurement invariance of the 4-factor model that fit 
excellently in MATCH data. 
 Another limitation of the present study was that the administration of identical 
measures may have varied between COMBINE and MATCH. For instance, the ROC 
curve analyses of the DrInC differed between COMBINE and MATCH, which may be 
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the result of how this measure was administered. The DrInC was inconsistently 
administered to individuals who reported total abstinence during the assessment window 
in Project MATCH and was administered to all individuals in the COMBINE Study, 
regardless of drinking status. These differences in assessment administration could 
explain why ROC curve results were inconsistent between the two studies. Further, the 
bivariate correlations had mixed results than were predicted for MATCH (but not 
COMBINE), which may indicate the DrInC as administered in MATCH was unstable 
psychometrically. Future administrations of the DrInC in other longitudinal studies may 
help elucidate these nuances to identify if the DrInC is poorly suited for longitudinal 
research or if methodology employed in MATCH was ill-suited for the DrInC. 
 Similarly, two of the three measures that performed most strongly in the present 
analyses (the BSI and WHOQOL-BREF) were only administered in the COMBINE 
Study. COMBINE was a smaller and more homogeneous sample than Project MATCH 
(primarily due to more strict alcohol consumption and diagnostic inclusion criteria in 
COMBINE). It is unclear how these two measures may perform in more heterogeneous 
samples. The current findings may not be generalizable to other studies and replication of 
the present findings is warranted.  
 Finally, findings from the present study may be limited by the fact that the full 
samples in COMBINE and MATCH were used. Analyses from Project MATCH included 
both aftercare and outpatient arms, which had different demographic characteristics and 
different levels of AUD severity (the aftercare arm had greater baseline drinking and 
severity than the outpatient arm). These differences may be one factor that could have 
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hurt the psychometrics of examined measures. Findings from the present study should be 
examined in other studies to attempt replication. 
Future Directions 
 Findings from the present study highlight strengths in several non-consumption 
measures for use in AUD treatment research. However, the present study also 
demonstrates that not all measures are created equally. For instance, although both the 
WHOQOL-BREF and the SF-12 are purported to measure quality of life, the SF-12 was 
non-invariant across time. Examining the items reveals that many items are “double-
barreled,” meaning they essentially ask more than one question per item (e.g., “…how 
much of the time has your physical health or emotional problems interfered with your 
social activities…”), which is particularly problematic when a measure was 
conceptualized as measuring two separate factors: physical and psychological health. 
These “double-barreled” items may be problematic for invariance of a measure across 
time because participants may respond predominantly to one aspect of the question item 
(e.g., physical health interference in social activities) at one timepoint and to another 
aspect of the question (e.g., emotional problem interference in social activities) at another 
timepoint. Careful development of question items comprising measures to avoid “double-
barreled” items and other pitfalls of measurement development and refinement are 
essential in future research (see recommendations by DeVellis, 2012; Miller et al., 2009). 
As the measures currently exist, it is recommended that future research use the 
WHOQOL-BREF rather than the SF-12 to assess changes in quality of life over time. 
 In addition to highlighting the need for future research to refine existing and 
develop new measures of non-consumption constructs, future research should prioritize 
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consistent administration of assessment tools. Assessments should be administered at 
multiple timepoints whenever possible, so future research can expand the extant 
knowledge of measurement invariance of commonly used assessment tools. The 
measurement non-invariance of several measures examined in the present study 
highlights the need for future research on testing for measurement invariance across time 
as well as across other domains such as gender, race, treatment sample, and other 
demographic characteristics. 
 Most importantly, the present study highlights the promise of several non-
consumption measures as viable means of examining clinically meaningful outcomes in 
AUD treatment research beyond changes in alcohol consumption alone. Accordingly, 
future researchers are supported in expanding their definitions of treatment success to 
include at least psychological health (via the BSI and BDI) and quality of life (via the 
WHOQOL-BREF). Additional research is needed to continue this vein of research to 
discover and develop other potentially viable measures that map onto definitions of 
treatment success used by clinicians as well as clients and their loved ones (Kaskutas et 
al., 2014; Neale et al., 2014). Future research need not rely solely upon consumption-
based outcome variables due to a lack of information on which measures are appropriate 
to use in AUD treatment research. Several non-consumption measures showed promise 
and more measures could be refined and developed to allow researchers to further 
enhance their ability to examine treatment efficacy using non-consumption outcomes.   
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Figure 1 
Summary of methods used in the present study 
 
Note. (C) = COMBINE Study; (M) = Project MATCH. Abbreviated measure names are: Drinker 
Inventory of Consequences (DrInC), Short Inventory of Problems (SIP), Addiction Severity 
Index (ASI), Alcohol Abstinence Self-Efficacy Scale (AASE), Obsessive-Compulsive Drinking 
Scale (OCDS), Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), Spielberger 
State-Trait Inventory (SSTI), World Health Organization Quality of Life brief version 
(WHOQOL-BREF), Health Survey (SF-12), Psychosocial Functioning Inventory (PFI). 
Abbreviated terms are: WHO = World Health Organization; DDD = drinks per drinking day; 
MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days), CCO = Composite 
Clinical Outcome, mod = moderate. 
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Table 1 
Demographic, design, and exclusion criteria for COMBINE and MATCH 
 COMBINE MATCH 
Demographic characteristic   
Sample size 1383 1726 
Gender -- % Male 69.1% 75.7% 
Age – Mean (SD) 44.4 (10.2) 40.2 (10.9) 
Ethnicity -- % White 76.8% 80.0% 
Marital status -- % Married, in relationship 46.3% 41.4% 
Employment status -- % Full or part-time 71.4% 82.1% 
Higher education or equivalent 70.6% 53.4% 
Design   
Randomization to treatment 9 groups 3 groups 
Length of treatment 16 weeks 12 weeks  
Follow-up assessments 12 months 12 months 
Exclusion criteria   
Age 18+ 18+ 
Meet criteria for abuse/dependence Past year Past year 
Reading level Literate 6th grade 
Comorbid psychiatric diagnoses X X 
Unable to identify collateral informant  X 
Severe cognitive impairment  X 
Residential instability  X 
Other illicit drug dependence X X 
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Table 2  
Outcome variables and their corresponding measures and timepoints available in COMBINE and MATCH  
Variable Measure in COMBINE (C) or 
MATCH (M) 
Timepoint(s) assessed in COMBINE (C) or MATCH (M) 
Alcohol/ 
Drug use 
Form-90 (C, M) Pre-treatment (C, M), During-treatment (C, M), Post-
treatment (C, M) 
 
Drinking 
Consequences
/Severity 
Drinker Inventory of Consequences/ 
Short Inventory of Problems 
(DrInC/SIP; C, M) 
 
Pre-treatment (C, M), During-treatment (C, M), Post-
treatment (C, M) 
Addiction Severity Index (ASI; M) Pre-treatment (M), During-treatment (M), Post-treatment 
(M) 
 
Mental health Brief Symptom Inventory (BSI; C) Pre-treatment (C), During-treatment (C), Post-treatment 
(C) 
 
Beck Depression Inventory (BDI; 
M) 
 
Spielberger State-Trait Inventory 
(SSTI; M) 
Pre-treatment (M), During-treatment (M), Post-treatment 
(M) 
 
Pre-treatment (M), During-treatment (M), Post-treatment 
(M) 
  
Craving/ 
Temptation 
Alcohol Abstinence Self-Efficacy 
(AASE; C, M) 
 
Obsessive-Compulsive Drinking 
Scale (OCDS; C) 
 
Pre-treatment (C, M), During-treatment (C, M), Post-
treatment (C, M) 
 
Pre-treatment (C), During-treatment (C), Post-treatment 
(C) 
Temptation/craving items during 
treatment (M) 
Pre-treatment (M), During-treatment (M), Post-treatment 
(M) 
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Quality of 
life/ 
Functioning 
World Health Organization Quality 
of Life (WHOQOL-BREF; C) 
 
Pre-treatment (C), During-treatment (C), Post-treatment 
(C) 
Health Survey (SF-12; C) Pre-treatment (C), During-treatment (C), Post-treatment 
(C) 
 
 Psychosocial Functioning Inventory 
(PFI; M) 
Pre-treatment (M), During-treatment (M), Post-treatment 
(M) 
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Table 3 
Outcome variables and the measures hypothesized to have convergent (+, significant positive correlation; -, significant 
negative correlation) validity in COMBINE and MATCH 
 
Form-
90 
DrInC, 
ASI 
BSI, 
SSTI, 
BDI 
OCDS, 
Temptation/ 
craving 
items 
PFI, 
WHOQOL-
BREF 
SF-12 ESI AASE AAI 
Form-90  +  +    - - 
DrInC, ASI +   + - - -  - 
BSI, SSTI, 
BDI 
    - - -   
OCDS, 
Temptation/ 
craving  
+ +        
PFI, 
WHOQOL-
BREF 
 - -       
SF-12  - -       
ESI  - -       
AASE -         
AAI - -        
Note. Abbreviated measure names are: Drinker Inventory of Consequences (DrInC), Addiction Severity Index (ASI), Brief Symptom 
Inventory (BSI), Spielberger State-Trait Inventory (SSTI), Beck Depression Inventory (BDI), Obsessive-Compulsive Drinking Scale 
(OCDS), Psychosocial Functioning Inventory (PFI), World Health Organization Quality of Life brief version (WHOQOL-BREF), 
Health Survey (SF-12), Employment Status and Income (ESI), Alcohol Abstinence Self-Efficacy Scale (AASE), and Alcoholics 
Anonymous Involvement (AAI).  
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Table 4 
Descriptive statistics and Cohen’s d effect sizes for measures used in the present study at 
baseline, post-treatment (post-tx), and 12-month follow-up (12mo) 
   N M (SD) Cohen’s d 
Percent Days 
Abstinent: 
COMBINE Study 
 Baseline: 1383 21.41 (22.50) Baseline to Post-
tx: 1.809 
Post-Tx: 1288 72.66 (33.49) Post-tx to 12mo: 
0.277 
12mo: 1099 62.63 (39.12) Baseline to 12mo: 
1.331 
Percent Days 
Abstinent: Project 
MATCH 
 Baseline: 1725 30.90 (29.96) Baseline to Post-
tx: 1.786 
Post-Tx: 1657 83.17 (28.51) Post-tx to 12-
moth: 0.208 
12mo: 1594 76.69 (33.55) Baseline to 12mo: 
1.443 
Percent Heavy 
Drinking Days: 
COMBINE Study 
 Baseline: 1383 70.52 (26.57) Baseline to Post-
tx: 1.919 
Post-Tx: 1288 17.54 (28.69) Post-tx to 12mo: 
0.275 
12mo: 1171 26.20 (34.27) Baseline to 12mo: 
1.461 
Percent Heavy 
Drinking Days: 
Project MATCH 
 Baseline: 1725 63.18 (31.43) Baseline to Post-
tx: 1.780 
Post-Tx: 1657 12.46 (25.09) Post-tx to 12mo: 
0.156 
12mo: 1594 16.71 (29.17) Baseline to 12mo: 
1.530 
DrInC: COMBINE 
Study 
 Baseline: 1381 47.61 (20.42) Baseline to Post-
tx: 1.735  
Post-Tx: 1098 13.36 (18.85) Post-tx to 12mo: 
0.322 
12mo: 965 19.89 (21.81) Baseline to 12mo: 
1.320 
Physical Health 
Subscale 
Baseline: 1381 9.28 (4.36) Baseline to Post-
tx: 1.607 
Post-Tx: 1098 2.61 (3.87) Post-tx to 12mo: 
0.320 
12mo: 965 3.95 (4.53) Baseline to 12mo: 
1.203 
Interpersonal 
Subscale 
Baseline: 1381 10.06 (6.01) Baseline to Post-
tx: 1.389 
Post-Tx: 1098 2.60 (4.44) Post-tx to 12mo: 
0.302 
12mo: 965 4.06 (5.25) Baseline to 12mo: 
1.051 
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 Intrapersonal 
Subscale 
Baseline: 1381 14.44 (5.66) Baseline to Post-
tx: 1.749 
Post-Tx: 1098 4.45 (5.78)  Post-tx to 12mo: 
0.292 
12mo: 965 6.26 (6.66) Baseline to 12mo: 
1.343 
Impulse 
Subscale 
Baseline: 1381 7.56 (4.25) Baseline to Post-
tx: 1.414 
Post-Tx: 1098 2.11 (3.29)  Post-tx to 12mo: 
0.318 
12mo: 965 3.24 (3.83) Baseline to 12mo: 
1.058 
Social 
Responsibility 
Subscale 
Baseline: 1381 6.27 (4.15) Baseline to Post-
tx: 1.260 
Post-Tx: 1098 1.60 (3.04) Post-tx to 12mo: 
0.242 
12mo: 965 2.39 (3.46) Baseline to 12mo: 
1.000 
DrInC: Project 
MATCH 
 Baseline: 1703 52.63 (23.32) Baseline to Post-
tx: 0.680 
Post-Tx: 985 35.86 (26.78) Post-tx to 12mo: 
0.323 
12mo: 789 27.50 (24.70) Baseline to 12mo: 
1.057 
 Physical Health 
Subscale 
Baseline: 1626 9.48 (4.94) Baseline to Post-
tx: 0.666 
Post-Tx: 966 6.14 (5.13) Post-tx to 
12moFU: 0.204 
12mo: 818 5.12 (4.85) Baseline to 12mo: 
0.945 
Interpersonal 
Subscale 
Baseline: 1558 12.21 (6.98) Baseline to Post-
tx: 0.568 
Post-Tx: 942 8.17 (7.34) Post-tx to 12mo: 
0.295 
12mo: 807 6.09 (6.72) Baseline to 12mo: 
0.888 
Intrapersonal 
Subscale 
Baseline: 1626 14.51 (6.02) Baseline to Post-
tx: 0.653 
Post-Tx: 964 10.38 (6.81) Post-tx to 12mo: 
0.297 
12mo: 819 8.31 (7.16) Baseline to 12mo: 
0.965 
 Impulse 
Subscale 
Baseline: 1572 8.69 (5.10) Baseline to Post-
tx: 0.503 
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Post-Tx: 967 6.06 (5.43) Post-tx to 12mo: 
0.540 
12mo: 820 3.41 (4.21) Baseline to 12mo: 
1.097 
Social 
Responsibility 
Subscale 
Baseline: 1598 7.49 (4.71) Baseline to Post-
tx: 0.591 
Post-Tx: 964 4.71 (4.69) Post-tx to 12mo: 
0.004 
12mo: 822 4.73 (4.56) Baseline to 12mo: 
0.592 
ASI Psychiatric 
Severity: Project 
MATCH 
 Baseline: 1714 0.21 (0.20) Baseline to Post-
tx: 0.358 
Post-Tx: 1566 0.14 (0.19) Post-tx to 12mo: 
0.053 
12mo: 1554 0.13 (0.19) Baseline to 12mo: 
0.410 
ASI Family 
History: Project 
MATCH 
 Baseline: 1726 2.65 (48.04) - 
ASI Legal Status: 
Project MATCH 
 Baseline: 1726 141.90 
(384.71) 
- 
OCDS: COMBINE 
Study 
 Baseline: 1383 26.60 (8.20) Baseline to Post-
tx: 1.762 
Post-Tx: 1101 11.25 (9.32) - 
12mo: 2 22.50 (6.36) - 
AASE: COMBINE 
Study 
 Baseline: 1382 113.26 
(15.39) 
Baseline to Post-
tx: 0.101 
 Post-Tx: 1103 114.78 
(14.71) 
- 
Confidence 
Subscale 
Baseline: 1377 2.61 (0.74) Baseline to Post-
tx: 1.078 
Post-Tx: 1100 3.50 (0.92) - 
Temptation 
Subscale 
Baseline: 1374 3.11 (0.78) Baseline to Post-
tx: 1.022 
Post-Tx: 1093 2.28 (0.85) - 
AASE: Project 
MATCH 
 Baseline: 1700 117.37 
(21.48) 
Baseline to Post-
tx: 0.130 
Post-Tx: 1557 114.56 
(21.87) 
- 
Confidence 
Subscale 
Baseline: 1662 3.06 (0.92) Baseline to Post-
tx: 0.469 
Post-Tx: 1528 3.51 (1.00) - 
Temptation 
Subscale 
Baseline: 1688 2.91 (0.90) Baseline to Post-
tx: 0.674 
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Post-Tx: 1545 2.31 (0.88) - 
Temptation Item: 
Project MATCH 
 Baseline: 1531 2.66 (1.34) - 
AAI: Project 
MATCH 
 Baseline: 1624 4.29 (2.60) - 
BSI: COMBINE 
Study 
 Baseline: 1356 60.29 (10.91) Baseline to Post-
tx: 0.695 
Post-Tx: 1101 52.32 (12.11) Post-tx to 12mo: 
0.031 
12mo: 959 51.93 (13.18) Baseline to 12mo: 
0.702 
 Somatic 
Subscale 
Baseline: 1356 54.50 (10.37) Baseline to Post-
tx: 0.467 
Post-Tx: 1101 49.89 (9.24) Post-tx to 12mo: 
0.123 
12mo: 959 51.10 (10.14) Baseline to 12mo: 
0.331 
Obsessive 
Compulsive 
Subscale 
Baseline: 1356 58.69 (10.75) Baseline to Post-
tx: 0.560 
Post-Tx: 1101 52.66 (10.78) Post-tx to 12mo: 
0.014 
12mo: 959 52.81 (11.38) Baseline to 12mo: 
0.534 
Interpersonal 
Sensitivity 
Subscale 
Baseline: 1356 56.75 (10.96) Baseline to Post-
tx: 0.405 
Post-Tx: 1101 52.44 (10.24) Post-tx to 12mo: 
0.061 
12mo: 959 51.81 (10.45) Baseline to 12mo: 
0.459 
Depression 
Subscale 
Baseline: 1356 61.55 (10.60) Baseline to Post-
tx: 0.603 
Post-Tx: 1101 55.15 (10.64) Post-tx to 12mo: 
0.001 
12mo: 959 55.16 (11.15) Baseline to 12mo: 
0.590 
Anxiety 
Subscale 
Baseline: 1356 58.37 (11.48) Baseline to Post-
tx: 0.628 
Post-Tx: 1101 51.26 (11.11) Post-tx to 12mo: 
0.012 
12mo: 959 51.12 (11.44) Baseline to 12mo: 
0.632  
Hostility 
Subscale 
Baseline: 1356 55.68 (9.65) Baseline to Post-
tx: 0.584 
Post-Tx: 1101 50.04 (9.67) Post-tx to 12mo: 
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0.103 
12mo: 959 49.32 (9.93) Baseline to 12mo: 
0.651 
Phobic Anxiety 
Subscale 
Baseline: 1356 53.43 (9.45) Baseline to Post-
tx: 0.262 
Post-Tx: 1101 51.10 (8.13) Post-tx to 12mo: 
0.025 
12mo: 959 50.89 (8.40) 0.281 
Paranoia 
Subscale 
Baseline: 1356 54.53 (10.45) Baseline to Post-
tx: 0.304 
Post-Tx: 1101 51.47 (9.61) Post-tx to 12mo: 
0.103 
12mo: 959 50.46 (9.97) Baseline to 12mo: 
0.397 
Psychoticism 
Subscale 
Baseline: 1356 63.29 (10.09) Baseline to Post-
tx: 0.633 
Post-Tx: 1101 56.73 (10.69) Post-tx to 12mo: 
0.006 
12mo: 959 56.67 (11.00) Baseline to 12mo: 
0.632 
BDI: Project 
MATCH 
 Baseline: 1618 10.17 (8.24) Baseline to Post-
tx: 0.322 
Post-Tx: 1532 7.57 (7.87) Post-tx to 12mo: 
0.045 
12mo: 1505 7.94 (8.40) Baseline to 12mo: 
0.268 
SSTI: Project 
MATCH (full 
SSTI) 
 Baseline: 1553 27.70 (7.14) - 
SSTI: Project 
MATCH (items 
used in factor 
analyses) 
 Baseline: 1553 25.79 (6.67) - 
WHOQOL-BREF: 
COMBINE Study 
 Baseline: 1351 87.94 (13.44) Baseline to Post-
tx: 0.679 
Post-Tx: 1062 97.67 (15.38) Post-tx to 12mo: 
0.257 
12mo: 954 93.88 (14.06) Baseline to 12mo: 
0.434 
Physical Health 
Subscale 
Baseline: 1351 27.29 (4.30) Baseline to Post-
tx: 0.420 
Post-Tx: 1060 29.11 (4.38) Post-tx to 12mo: 
0.037 
12mo: 954 28.95 (4.36) Baseline to 12mo: 
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0.384 
Psychological 
Health Subscale 
Baseline: 1351 21.04 (3.97) Baseline to Post-
tx: 0.417 
Post-Tx: 1060 22.75 (4.27) Post-tx to 12mo: 
0.022 
12mo: 954 22.84 (4.03)  Baseline to 12mo: 
0.451 
Social Subscale Baseline: 1351 9.84 (2.63) Baseline to Post-
tx: 0.373 
Post-Tx: 1060 10.82 (2.62) Post-tx to 12mo: 
0.008 
12mo: 953 10.84 (2.52) Baseline to 12mo: 
0.389 
Environment 
Subscale 
Baseline: 1351 29.77 (5.44) Baseline to Post-
tx: 0.280 
Post-Tx: 1060 31.31 (5.57) Post-tx to 12mo: 
0.007 
12mo: 954 31.27 (5.49) Baseline to 12mo: 
0.275 
SF-12: COMBINE 
Study 
 Baseline: 1357 42.28 (7.14)  Baseline to Post-
tx: 0.710 
Post-Tx: 1102 47.13 (6.43) Post-tx to 12mo: 
0.275 
12mo: 951 45.26 (7.18) Baseline to 12mo: 
0.416 
 Physical Health 
Subscale 
Baseline: 1346 0.27 (0.83) Baseline to Post-
tx: 0.129 
Post-Tx: 1099 0.37 (0.70) Post-tx to 12mo: 
0.244 
12mo: 948 0.18 (0.86) Baseline to 12mo: 
0.107 
Psychological 
Health Subscale 
Baseline: 1346 -0.86 (1.10) Baseline to Post-
tx: 0.760 
Post-Tx: 1099 -0.07 (0.96) Post-tx to 12mo: 
0.130 
12mo: 948 -0.20 (1.04) Baseline to 12mo: 
0.614 
PFI: Project 
MATCH 
 Baseline: 1695 50.91 (11.42) Baseline to Post-
tx: 0.532 
Post-Tx: 1556 56.88 (10.98) - 
Note. Abbreviated measure names are: Drinker Inventory of Consequences (DrInC), Addiction 
Severity Index (ASI), Brief Symptom Inventory (BSI), Spielberger State-Trait Inventory (SSTI), 
Beck Depression Inventory (BDI), Obsessive-Compulsive Drinking Scale (OCDS), Psychosocial 
Functioning Inventory (PFI), World Health Organization Quality of Life brief version 
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(WHOQOL-BREF), Health Survey (SF-12), Employment Status and Income (ESI), Alcohol 
Abstinence Self-Efficacy Scale (AASE), and Alcoholics Anonymous Involvement (AAI).  
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Table 5 
Frequencies for dichotomous consumption outcome variables used in Receiver Operating 
Characteristic (ROC) Curve analyses at post-treatment (post-tx) and 12-month follow-up (12mo) 
 
COMBINE Study Project MATCH 
Post-tx Abstinence 
0 = 829 
1 = 459 
N =  1288 
0 = 807 
1 =  850 
N =  1657 
Post-tx Heavy Drinking 
0 = 858 
1 = 630 
N = 1288 
0 = 1017 
1 = 640 
N =  1657 
Post-tx WHO risk: low risk or 
lower risk computed via DDD 
0 = 699 
1 = 589 
N = 1288 
0 = 692 
1 = 965 
N =  1657 
Post-tx WHO risk: low risk or 
lower risk computed via MXD 
0 = 751 
1 = 537 
N = 1288 
0 = 720 
1 = 937 
N =  1657 
Post-tx WHO risk: low risk or 
lower risk computed via DPD 
0 = 325 
1 = 963 
N =  1288 
0 = 304 
1 = 1353 
N =  1657 
Post-tx WHO risk: moderate 
risk or lower risk computed 
via DDD 
0 = 544 
1 = 744 
N = 1288 
0 = 592 
1 = 1065 
N =  1657 
Post-tx WHO risk: moderate 
risk or lower risk computed 
via MXD 
0 = 641 
1 = 647 
N =  1288 
0 = 645 
1 = 1012 
N =  1657 
Post-tx WHO risk: moderate 
risk or lower risk computed 
via DPD 
0 = 199 
1 = 1089 
N =  1288 
0 = 219 
1 = 1438 
N =  1657 
Post-tx Composite clinical 
Outcome: Abstinent 
0 = 666 
1 = 471 
N = 1137 
0 = 1057 
1 = 599 
N =  1656 
Post-tx Composite clinical 
Outcome: Moderate drinking 
or abstinent 
0 = 348 
1 = 789 
N =  1137 
0 = 850 
1 = 806 
N = 1656 
Post-tx Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0 = 98 
1 = 1039 
N =  1137 
0 = 531 
1 = 1125 
N =  1656 
1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0 = 473 
1 = 763 
N = 1236 
0 = 571 
1 = 1069 
N = 1640 
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1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0 = 261 
1 = 975 
N = 1236 
0 = 335 
1 = 1305 
N =  1640 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0 = 686 
1 = 550 
N = 1236 
0 = 784 
1 = 856 
N =  1640 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0 = 493 
1 = 743 
N =  1236 
0 = 624 
1 = 1016 
N = 1640 
12mo Abstinence 
0 = 817 
1 = 355 
N = 1172 
0 = 847 
1 = 747 
N = 1594 
12mo Heavy Drinking 
0 = 539 
1 = 633 
N = 1172 
0 = 923 
1 = 671 
N =  1594 
12mo WHO risk: low risk or 
lower risk computed via DDD 
0 = 719 
1 = 453 
N =  1172 
0 = 729 
1 = 865 
N =  1594 
12mo WHO risk: low risk or 
lower risk computed via MXD 
0 = 756 
1 = 416 
N = 1172 
0 = 763 
1 = 831 
N =  1594 
12mo WHO risk: low risk or 
lower risk computed via DPD 
0 = 448 
1 = 724 
N = 1172 
0 = 384 
1 = 1210 
N =  1594 
12mo WHO risk: moderate 
risk or lower risk computed 
via DDD 
0 = 581 
1 = 591 
N = 1172 
0 = 615 
1 = 979 
N =  1594 
12mo WHO risk: moderate 
risk or lower risk computed 
via MXD 
0 = 646 
1 = 526 
N = 1172 
0 = 682 
1 = 912 
N =  1594 
12mo WHO risk: moderate 
risk or lower risk computed 
via DPD 
0 = 323 
1 = 849 
N = 1172 
0 = 255 
1 = 1339 
N =  1594 
12mo Composite clinical 
Outcome: Abstinent 
0 = 750 
1 = 284 
N = 1034 
0 = 1024 
1 = 581 
N =  1605 
12mo Composite clinical 
Outcome: Moderate drinking 
or abstinent 
0 = 554 
1 = 480 
N =  1034 
0 = 827 
1 = 778 
N = 1605 
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12mo Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0 = 234 
1 = 800 
N =  1034 
0 = 488 
1 = 1117 
N =  1605 
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Table 6 
Summary of Psychometric Findings across Measures and Methods (0 = Poor Psychometric Qualities; 1 = Mixed or Modest 
Psychometric Qualities; and 2 = Acceptable to Excellent Psychometric Qualities) 
Measure (Study: COMBINE (C) or MATCH (M)) ROC Reliability Convergent 
Validity 
CFA Invariance 
 
Total 
Points/ 
Possible 
Points 
Alcohol Abstinence Self-Efficacy Scale (AASE) (C; 
M) 
0 1 1 1 2 5/10 
AASE-Confidence (C; M) 2 N/A N/A N/A N/A 2/2 
AASE-Temptation (C; M) 2 N/A N/A N/A N/A 2/2 
Addiction Severity Index (M) 0 0 0 0 0 0/10 
Beck Depression Inventory (M) 1 2 2 2 2 9/10 
Brief Symptom Inventory (C) 1 2 2 2 2 9/10 
Drinker Inventory of Consequences (C; M) 1 2 1 1 2 7/10 
Obsessive-Compulsive Drinking Scale (C) 2 2 2 1 1 8/10 
Psychosocial Functioning Inventory (M) 1 2 2 1 0 6/10 
Short Form Health Survey-12 (C) 1 2 2 1 0 6/10 
Spielberger State-Trait Inventory (M) 0 2 1 2 N/A 5/8 
WHO Quality of Life Scale - Brief (C) N/A 2 2 1 2 7/8 
       
Note. ROC. Sensitivity/specificity scores of 0 indicated area under the curve (AUC) < 0.650 across all outcomes; 1 point indicated 
AUC > 0.650 and < 0.700 or mixed results across studies or across consumption outcomes; 2 points indicated AUC > 0.700 in both 
COMBINE and MATCH or for most outcomes. Internal consistency reliability scores of 0 indicated α < 0.70; 1 point indicated α > 
0.70 and < 0.80 or mixed results across studies; 2 points indicated α > 0.80 in both COMBINE and MATCH. Convergent validity 
results with scores of 0 indicated non-significant (p > 0.05) or at least one correlation in the opposite direction than was expected; 1 
point indicated significant correlations with some but not all the expected measures or mixed results across studies; 2 points indicated 
significant correlations in the expected direction for all measures in both COMBINE and MATCH. Confirmatory factor analysis 
(CFA) results with scores of 0 indicated RMSEA > 0.08 or CFI or TLI < 0.90; 1 point indicated RMSEA < 0.08 and > 0.06 and/or CFI 
or TLI > 0.90 and < 0.95 or mixed results across studies; 2 points indicated RMSEA < 0.06 and CFI or TLI > 0.95 in both COMBINE 
and MATCH. Measurement invariance results with scores of 0 indicated non-invariance at the configural level or did not proceed to 
invariance testing due to poor model fit; 1 point indicated at least adequate model fit through the metric invariance testing (constraint 
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of the factor loadings for equivalence) or mixed results across both studies; 2 points indicated good model fit through strong 
invariance testing (highest possible level of invariance for categorical data) in both COMBINE and MATCH.  
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Table 7 
Model results for CFA and measurement invariance testing 
Measure (Dataset) CFA Model Invariance Testing Model RMSEA (90% CI) CFI TLI 
AASE 
(COMBINE) 
4-factors based on 
DiClemente et al., 1994 
structure 
 0.050 (0.048, 
0.053) 
0.919 0.914 
  Configural: Baseline to 
Post-Treatment 
0.030 (0.029, 
0.031) 
0.964 0.963 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.029 (0.028, 
0.030) 
0.964 0.964 
  Thresholds Constrained: 
Baseline to Post-Treatment 
0.033 (0.032, 
0.034) 
0.953 0.954 
AASE (MATCH) 4-factors based on 
DiClemente et al., 1994 
structure* 
 0.060 (0.058, 
0.062) 
0.866 0.857 
AASE (MATCH 
aftercare arm only) 
4-factors based on 
DiClemente et al., 1994 
structure 
 0.081 (0.078, 
0.084) 
0.879 0.872 
AASE (MATCH 
outpatient arm 
only) 
4-factors based on 
DiClemente et al., 1994 
structure 
 0.050 (0.047, 
0.053) 
0.931 0.926 
  Configural: Baseline to 
Post-Treatment 
0.027 (0.026, 
0.029) 
0.917 0.914 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.027 (0.026, 
0.029) 
0.915 0.913 
  Thresholds Constrained: 
Baseline to Post-Treatment 
0.028 (0.026, 
0.029) 
0.912 0.912 
ASI (MATCH) 3-Factor Solution based on 
McLellan et al., 1992 
structure* 
 N/A (failed 
convergence) 
N/A N/A 
 Modified 3-Factor Solution 
based on McLellan et al., 
 N/A (failed 
convergence) 
N/A N/A 
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1992 structure with items 
ASIAF1, ASIAF2, ASIAF3, 
ASIAF6, ASIAF7, ASIAF8 
specified as categorical per 
limited distributions and 
with item ASIAL13 
removed due to high 
correlations with other 
variables and sparseness in 
item endorsement. 
BDI (MATCH) 2-factors (cognitive-
affective and somatic 
factors) 
 0.030 (0.025, 
0.035) 
0.978 0.975 
  Configural: Baseline to 
Post-Treatment 
0.019 (0.017, 
0.021) 
0.971 0.970 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.018 (0.016, 
0.020) 
0.973 0.972 
  Thresholds Constrained: 
Baseline to Post-Treatment 
0.019 (0.017, 
0.021) 
0.968 0.969 
 3-factors (negative attitude, 
performance impairment, 
and somatic factors) 
 0.027 (0.021, 
0.032) 
0.982 0.980 
  Configural: Baseline to 
Post-Treatment 
0.019 (0.017, 
0.020) 
0.973 0.971 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.018 (0.016, 
0.020) 
0.975 0.974 
  Thresholds Constrained: 
Baseline to Post-Treatment 
0.019 (0.017, 
0.021) 
0.970 0.971 
BSI (COMBINE) 9-factors based on 
Derogatis & Melisaratos, 
1983 structure 
 0.022 (0.019, 
0.025) 
0.975 0.974 
  Configural: Baseline to 0.011 (0.010, 0.981 0.980 
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Post-Treatment 0.012) 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.011 (0.009, 
0.012) 
0.982 0.981 
  Thresholds Constrained: 
Baseline to Post-Treatment 
0.012 (0.011, 
0.013) 
0.977 0.977 
DrInC (COMBINE) 5-factors based on original 
conceptualization* 
 0.044 (0.041, 
0.046) 
0.900 0.894 
 1-factor based on previously 
published models* 
 0.051 (0.049, 
0.054) 
0.861 0.854 
 3-factor solution based on 
my conceptualization of the 
DrInC as comprised of 
consequences that occur 
commonly, moderately, and 
rarely 
 0.041 (0.038, 
0.043) 
0.920 0.916 
  Configural: Baseline to 
Post-Treatment 
0.017 (0.016, 
0.019) 
0.975 0.974 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.019 (0.018, 
0.020) 
0.969 0.968 
  Thresholds Constrained: 
Baseline to Post-Treatment 
0.024 (0.023, 
0.025) 
0.951 0.952 
DrInC (MATCH) 3-factor solution based on 
my conceptualization of the 
DrInC as comprised of 
consequences that occur 
commonly, moderately, and 
rarely 
 0.040 (0.038, 
0.042) 
0.908 0.904 
  Configural: Baseline to 
Post-Treatment 
0.018 (0.017, 
0.019) 
0.945 0.944 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.018 (0.017, 
0.018) 
0.946 0.946 
  Thresholds Constrained: 0.018 (0.017, 0.941 0.942 
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Baseline to Post-Treatment 0.019) 
SIP (COMBINE) 5-factors based on original 
conceptualization 
 0.061 (0.053, 
0.069) 
0.969 0.960 
  Configural: Baseline to 
Post-Treatment 
0.086 (0.084, 
0.086) 
0.894 0.883 
  Loadings Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
  Thresholds Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
 1-factor based on previously 
published models* 
 0.109 (0.102, 
0.116) 
0.890 0.871 
SIP (MATCH) 5-factors based on original 
conceptualization 
 0.077 (0.070, 
0.084) 
0.949 0.933 
  Configural: Baseline to 
Post-Treatment 
0.059 (0.057, 
0.061) 
0.894 0.883 
  Loadings Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
  Thresholds Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
OCDS 
(COMBINE) 
     
 2-factor model based on 
Ansseau et al., 2000; Anton 
2000; Cordero et al., 2009* 
 0.109 (0.102, 
0.117) 
0.852 0.823 
 2-factor model based on 
Ansseau et al., 2000; Anton 
2000; Cordero et al., 2009 
with consumption items 
 0.123 (0.114, 
0.131) 
0.869 0.837 
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removed* 
 3-factor model based on 
Roberts et al., 1999* 
 0.096 (0.089, 
0.104) 
0.889 0.863 
 3-factor model based on 
Kranzler et al., 1999* 
 0.104 (0.096, 
0.111) 
0.881 0.841 
 4-factor model based on 
Bohn et al., 1996* 
 0.100 (0.093, 
0.108) 
0.885 0.852 
 4-factor model based on 
Connor et al., 2008* 
 0.084 (0.076, 
0.091) 
0.920 0.897 
 4-factor model based on 
previous published 
structures, EFA results, and 
conceptualization of items 
 0.072 (0.062, 
0.082) 
0.968 0.956 
  Configural: Baseline to 
Post-Treatment 
0.032 (0.029, 
0.036) 
0.987 0.984 
  Loadings Constrained: 
Baseline to Post-Treatment 
0.035 (0.032, 
0.038) 
0.984 0.981 
  Thresholds Constrained: 
Baseline to Post-Treatment 
0.076 (0.073, 
0.079) 
0.910 0.912 
PFI (MATCH) 3-factor model based on 
original conceptualization 
of factors available in 
MATCH abbreviated 
version of the PFI 
 0.052 (0.047, 
0.057) 
0.933 0.923 
  Configural: Baseline to 
Post-Treatment 
0.042 (0.041, 
0.044) 
0.822 0.811 
  Loadings Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
  Thresholds Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
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SF-12 (COMBINE) 2-factor model based on 
previously published 
models 
 0.080 (0.071, 
0.090) 
0.951 0.939 
  Configural: Baseline to 
Post-Treatment 
0.075 (0.072, 
0.078) 
0.854 0.839 
  Loadings Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
  Thresholds Constrained: 
Baseline to Post-Treatment 
N/A (Not tested due 
to failed configural 
invariance) 
N/A N/A 
SSTI (MATCH) 
only administered 
at baseline 
2-factor model based on 
previously published 
models* 
 0.116 (0.109, 
0.122) 
0.902 0.884 
 4-factor model based on 
original conceptualization 
of 7 factors (items for 4 of 
the 7 factors were available 
in MATCH) 
 0.056 (0.048, 
0.064) 
0.976 0.969 
WHOQOL-BREF 
(COMBINE) 
4-factor, higher order model 
based on Skevington et al., 
2004 structure 
 0.050 (0.045, 
0.055) 
0.942 0.935 
  Model 1: Baseline to Week 
26 (N=1381) 
0.037 (0.035-0.038) 0.921 0.916 
  Model 2: Baseline to Week 
26   
0.035 (0.034-0.037) 0.926 0.923 
  Model 3: Baseline to Week 
26   
0.035 (0.033-0.037) 0.927 0.924 
  Model 4: Baseline to Week 
26   
0.033 (0.032-0.035) 0.927 0.931 
  Model 5: Baseline to Week 
26   
0.035 (0.033-0.036) 0.920 0.925 
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  Model 1: Week 26 to Week 
52   
0.042 (0.040-0.044) 0.917 0.912 
  Model 2: Week 26 to Week 
52   
0.040 (0.038-0.041) 0.924 0.921 
  Model 3: Week 26 to Week 
52   
0.039 (0.038-0.041) 0.925 0.922 
  Model 4: Week 26 to Week 
52   
0.039 (0.036-0.039) 0.925 0.929 
  Model 5: Week 26 to Week 
52   
0.037 (0.036-0.039) 0.926 0.930 
 4-factor model based on 
Jaracz et al., 2006 structure 
 0.053 (0.048-0.058) 0.944 0.936 
 4-factor model based on 
Trompenaars et al., 2005 
structure 
 0.053 (0.048-0.058) 0.938 0.930 
 4-factor model based on 
Yao & Wu, 2002 structure 
 Non-positive 
definite matrix 
N/A N/A 
 
Note. CFA results are for the replication split half sample unless specified as the first split half via * 
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Table 8 
Baseline measure internal consistency reliability 
Measure Subscale (from CFA) Cronbach’s Alpha 
AASE (COMBINE)  0.752* 
 Negative Affect 0.356 
 Social/Positive 0.341 
 Physical & Other Concern 0.162 
 Withdrawal & Urges 0.279 
AASE (MATCH)  0.841** 
 Negative Affect 0.557 
 Social/Positive 0.460 
 Physical & Other Concern 0.546 
 Withdrawal & Urges 0.458 
ASI  0.327 
BDI  0.889** 
 2-Factor Model: Cognitive-Affective 0.848** 
 2-Factor Model: Somatic 0.771* 
 3-Factor Model: Negative Attitudes 0.859** 
 3-Factor Model: Performance Impairment 0.739* 
 3-Factor Model: Somatic 0.478 
BSI  0.965** 
 Somatization 0.798* 
 Obsessive-Compulsive 0.862** 
 Depression 0.882** 
 Interpersonal Sensitivity 0.643 
 Hostility 0.790* 
 Anxiety 0.824** 
 Psychoticism 0.864** 
 Phobic Anxiety 0.786* 
 Paranoid Ideation 0.836** 
DrInC (COMBINE)  0.937** 
 Common Consequences 0.855** 
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 Moderately Common Consequences 0.905** 
 Rare Consequences 0.808** 
DrInC (MATCH)  0.938** 
 Common Consequences 0.833** 
 Moderately Common Consequences 0.905** 
 Rare Consequences 0.830** 
OCDS  0.852** 
PFI  0.867** 
 Subjective Role Performance 0.817** 
 Overall Social Role Performance 0.818** 
 Housemate/Roommate Role 0.531 
SF-12  0.874** 
 Physical Health 0.805** 
 Psychological Health 0.861** 
SSTI  0.887** 
 “Factor 1” by Forgays et al., 1997 0.746* 
 “Factor 2” by Forgays et al., 1997 0.865** 
 “Factor 4” by Forgays et al., 1997 0.496 
 “Factor 6” by Forgays et al., 1997 0.781* 
WHOQOL-BREF  0.901** 
 Physical Health 0.798* 
 Psychological Health 0.770* 
 Social Relationships 0.718* 
 Environment 0.812** 
 
Note. * indicates good internal consistency of α > 0.70 and < 0.80; ** indicates excellent internal consistency of α > 0.80.  
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Table 9 
Receiver operating characteristic curve area under the curve (AUC) results for the Brief Symptom Inventory (BSI) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes 
 
BSI 
total 
score 
SOM 
Factor 
OC 
Factor 
DEP 
Factor 
IS 
Factor 
HOS 
Factor 
ANX 
Factor 
PSY 
Factor 
PHOB 
Factor 
PARA 
Factor 
Post-tx Abstinence 0.628 0.613 0.617 0.626 0.622 0.602 0.606 0.600 0.566 0.575 
Post-tx Heavy Drinking 0.676 0.629 0.644 0.672 0.667 0.636 0.652 0.648 0.610 0.619 
Post-tx WHO risk: low risk or 
lower risk computed via DDD 
0.658 0.622 0.634 0.661 0.650 0.619 0.645 0.634 0.594 0.603 
Post-tx WHO risk: low risk or 
lower risk computed via MXD 
0.650 0.617 0.627 0.652 0.642 0.624 0.631 0.620 0.589 0.598 
Post-tx WHO risk: low risk or 
lower risk computed via DPD 
0.690 0.674 0.691 0.695 0.672 0.627 0.693 0.650 0.608 0.609 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DDD 
0.675 0.641 0.650 0.670 0.662 0.627 0.656 0.647 0.613 0.619 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
MXD 
0.670 0.634 0.645 0.667 0.662 0.633 0.650 0.641 0.606 0.614 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DPD 
0.724 0.683 0.714 0.718 0.695 0.666 0.731 0.655 0.624 0.623 
Post-tx Composite clinical 
Outcome: Abstinent 
0.638 0.624 0.619 0.639 0.636 0.612 0.622 0.610 0.575 0.583 
Post-tx Composite clinical 
Outcome: Moderate drinking or 
abstinent 
0.746 0.698 0.710 0.744 0.723 0.677 0.735 0.704 0.639 0.646 
Post-tx Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0.833 0.767 0.796 0.833 0.809 0.754 0.799 0.774 0.713 0.721 
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1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.603 0.569 0.587 0.606 0.595 0.567 0.605 0.585 0.569 0.573 
1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.591 0.529 0.568 0.601 0.564 0.581 0.589 0.565 0.535 0.539 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.511 0.581 0.588 0.616 0.592 0.581 0.599 0.593 0.568 0.574 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.585 0.550 0.574 0.584 0.570 0.567 0.580 0.566 0.550 0.554 
12mo Abstinence 0.545 0.549 0.543 0.555 0.543 0.557 0.541 0.539 0.508 0.512 
12mo Heavy Drinking 0.603 0.569 0.578 0.608 0.580 0.600 0.585 0.601 0.557 0.562 
12mo WHO risk: low risk or 
lower risk computed via DDD 
0.599 0.581 0.580 0.610 0.582 0.593 0.592 0.596 0.556 0.560 
12mo WHO risk: low risk or 
lower risk computed via MXD 
0.589 0.573 0.576 0.596 0.579 0.588 0.577 0.583 0.546 0.550 
12mo WHO risk: low risk or 
lower risk computed via DPD 
0.602 0.568 0.604 0.619 0.578 0.589 0.600 0.597 0.551 0.551 
12mo WHO risk: moderate risk 
or lower risk computed via 
DDD 
0.618 0.580 0.587 0.627 0.597 0.599 0.605 0.523 0.574 0.578 
12mo WHO risk: moderate risk 
or lower risk computed via 
MXD 
0.603 0.578 0.579 0.611 0.583 0.597 0.588 0.599 0.562 0.566 
12mo WHO risk: moderate risk 
or lower risk computed via 
DPD 
0.613 0.572 0.594 0.627 0.590 0.586 0.607 0.610 0.562 0.568 
12mo Composite clinical 
Outcome: Abstinent 
0.550 0.556 0.545 0.562 0.547 0.557 0.543 0.552 0.522 0.523 
12mo Composite clinical 0.625 0.586 0.604 0.639 0.612 0.619 0.606 0.620 0.571 0.574 
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Outcome: Moderate drinking or 
abstinent 
12mo Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0.708 0.638 0.686 0.706 0.648 0.691 0.677 0.686 0.647 0.650 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). BSI sub-scale factors are: Somatic symptoms (SOM), 
Obsessive-Compulsive symptoms (OC), Depressive symptoms (DEP), Interpersonal Sensitivity (IS), Hostility (HOS), Anxiety 
symptoms (ANX), Psychoticism symptoms (PSY), Phobic Anxiety symptoms (PHOB), and Paranoia symptoms (PARA). AUC > 
0.650 have been bolded and underlined for improved readability. 
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Table 10 
Receiver operating characteristic curve area under the curve (AUC) results for the Beck Depression Inventory (BDI) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes 
 
BDI total 
score 
2-Factor 
Solution: 
Cognitive 
Factor 
2-Factor 
Solution: 
Somatic 
Factor 
3-Factor 
Solution: 
Negative 
Affect Factor 
3-Factor 
Solution: 
Performance 
Impairment 
Factor 
3-Factor 
Solution: 
Somatic 
Factor 
Post-tx Abstinence 0.582 0.606 0.598 0.626 0.585 0.558 
Post-tx Heavy Drinking 0.597 0.636 0.616 0.654 0.604 0.571 
Post-tx WHO risk: low risk or 
lower risk computed via DDD 
0.598 0.633 0.619 0.653 0.605 0.575 
Post-tx WHO risk: low risk or 
lower risk computed via MXD 
0.589 0.625 0.612 0.645 0.602 0.569 
Post-tx WHO risk: low risk or 
lower risk computed via DPD 
0.653 0.689 0.706 0.701 0.680 0.658 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DDD 
0.600 0.641 0.624 0.659 0.611 0.577 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
MXD 
0.595 0.634 0.615 0.651 0.603 0.569 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DPD 
0.658 0.705 0.710 0.714 0.685 0.668 
Post-tx Composite clinical 
Outcome: Abstinent 
0.588 0.604 0.594 0.625 0.580 0.554 
Post-tx Composite clinical 
Outcome: Moderate drinking 
or abstinent 
0.613 0.640 0.639 0.665 0.615 0.585 
Post-tx Composite clinical 
Outcome: Heavy drinking OR 
0.624 0.656 0.655 0.678 0.633 0.596 
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problems, moderate drinking, 
or abstinent 
1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.630 0.608 0.593 0.626 0.579 0.563 
1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.586 0.584 0.570 0.592 0.573 0.537 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.604 0.587 0.570 0.606 0.562 0.541 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.555 0.538 0.530 0.551 0.531 0.508 
12mo Abstinence 0.596 0.558 0.556 0.574 0.553 0.523 
12mo Heavy Drinking 0.623 0.574 0.579 0.591 0.571 0.539 
12mo WHO risk: low risk or 
lower risk computed via DDD 
0.619 0.577 0.576 0.593 0.570 0.537 
12mo WHO risk: low risk or 
lower risk computed via MXD 
0.610 0.564 0.574 0.580 0.566 0.530 
12mo WHO risk: low risk or 
lower risk computed via DPD 
0.674 0.597 0.607 0.615 0.592 0.572 
12mo WHO risk: moderate 
risk or lower risk computed via 
DDD 
0.631 0.586 0.587 0.604 0.583 0.536 
12mo WHO risk: moderate 
risk or lower risk computed via 
MXD 
0.624 0.574 0.582 0.593 0.573 0.539 
12mo WHO risk: moderate 
risk or lower risk computed via 
DPD 
0.669 0.586 0.606 0.603 0.599 0.569 
12mo Composite clinical 0.623 0.565 0.566 0.582 0.564 0.533 
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Outcome: Abstinent 
12mo Composite clinical 
Outcome: Moderate drinking 
or abstinent 
0.667 0.595 0.604 0.617 0.593 0.558 
12mo Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0.681 0.621 0.630 0.635 0.622 0.572 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability.  
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Table 11 
Receiver operating characteristic curve area under the curve (AUC) results for the World Health Organization Quality of Life Brief 
scale (WHOQOL-BREF) for detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes 
 
WHOQOL-BREF 
total score 
Physical Factor 
Psychological 
Factor 
Social Factor 
Environment 
Factor 
12mo Abstinence 0.508 0.555 0.569 0.583 0.556 
12mo Heavy Drinking 0.643 0.620 0.630 0.627 0.609 
12mo WHO risk: low risk or 
lower risk computed via DDD 
0.631 0.604 0.615 0.620 0.603 
12mo WHO risk: low risk or 
lower risk computed via MXD 
0.623 0.595 0.604 0.616 0.595 
12mo WHO risk: low risk or 
lower risk computed via DPD 
0.632 0.616 0.635 0.612 0.579 
12mo WHO risk: moderate risk 
or lower risk computed via 
DDD 
0.664 0.638 0.652 0.642 0.629 
12mo WHO risk: moderate risk 
or lower risk computed via 
MXD 
0.644 0.618 0.630 0.632 0.610 
12mo WHO risk: moderate risk 
or lower risk computed via 
DPD 
0.651 0.633 0.659 0.627 0.591 
12mo Composite clinical 
Outcome: Abstinent 
0.610 0.589 0.609 0.597 0.581 
12mo Composite clinical 
Outcome: Moderate drinking or 
abstinent 
0.668 0.644 0.665 0.638 0.624 
12mo Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, or 
abstinent 
0.715 0.698 0.704 0.691 0.653 
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Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability.  
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Table 12 
Receiver operating characteristic curve area under the curve (AUC) results for the Obsessive-Compulsive Drinking Scale (OCDS) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes 
 
OCDS total 
score 
Factor 1 Factor 2 Factor 3 Factor 4 
Post-tx Abstinence 0.864 0.659 0.657 0.773 0.832 
Post-tx Heavy Drinking 0.846 0.671 0.697 0.775 0.826 
Post-tx WHO risk: low risk or lower risk computed via 
DDD 
0.846 0.668 0.683 0.766 0.825 
Post-tx WHO risk: low risk or lower risk computed via 
MXD 
0.863 0.668 0.674 0.780 0.838 
Post-tx WHO risk: low risk or lower risk computed via 
DPD 
0.868 0.669 0.708 0.751 0.851 
Post-tx WHO risk: moderate risk or lower risk 
computed via DDD 
0.819 0.667 0.710 0.763 0.806 
Post-tx WHO risk: moderate risk or lower risk 
computed via MXD 
0.844 0.667 0.689 0.768 0.823 
Post-tx WHO risk: moderate risk or lower risk 
computed via DPD 
0.876 0.684 0.758 0.763 0.851 
Post-tx Composite clinical Outcome: Abstinent 0.857 0.673 0.666 0.766 0.820 
Post-tx Composite clinical Outcome: Moderate drinking 
or abstinent 
0.919 0.726 0.771 0.821 0.888 
Post-tx Composite clinical Outcome: Heavy drinking 
OR problems, moderate drinking, or abstinent 
0.934 0.782 0.871 0.877 0.912 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.686 0.610 0.629 0.646 0.676 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.709 0.618 0.614 0.658 0.701 
2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.732 0.620 0.627 0.675 0.719 
2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.696 0.589 0.627 0.631 0.686 
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12mo Abstinence 0.709 0.604 0.566 0.643 0.695 
12mo Heavy Drinking 0.695 0.606 0.603 0.644 0.684 
12mo WHO risk: low risk or lower risk computed via 
DDD 
0.717 0.626 0.599 0.661 0.703 
12mo WHO risk: low risk or lower risk computed via 
MXD 
0.730 0.627 0.599 0.667 0.716 
12mo WHO risk: low risk or lower risk computed via 
DPD 
0.729 0.616 0.602 0.659 0.718 
12mo WHO risk: moderate risk or lower risk computed 
via DDD 
0.690 0.616 0.620 0.647 0.682 
12mo WHO risk: moderate risk or lower risk computed 
via MXD 
0.693 0.603 0.599 0.641 0.684 
12mo WHO risk: moderate risk or lower risk computed 
via DPD 
0.728 0.630 0.623 0.666 0.718 
12mo Composite clinical Outcome: Abstinent 0.734 0.614 0.587 0.681 0.721 
12mo Composite clinical Outcome: Moderate drinking 
or abstinent 
0.756 0.647 0.629 0.694 0.742 
12mo Composite clinical Outcome: Heavy drinking OR 
problems, moderate drinking, or abstinent 
0.737 0.668 0.672 0.716 0.722 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability.  
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Table 13 
Receiver operating characteristic curve area under the curve (AUC) results for the Drinker Inventory of Consequences (DrInC) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in the COMBINE Study 
 
COMBINE DrInC 
total score 
Factor 1 
(Common 
Consequences) 
Factor 2 
(Moderately 
Common 
Consequences) 
Factor 3 (Rare 
Consequences) 
Post-tx Abstinence 0.845 0.833 0.803 0.780 
Post-tx Heavy Drinking 0.845 0.840 0.824 0.782 
Post-tx WHO risk: low risk or lower risk computed via 
DDD 
0.841 0.835 0.810 0.775 
Post-tx WHO risk: low risk or lower risk computed via 
MXD 
0.843 0.834 0.807 0.774 
Post-tx WHO risk: low risk or lower risk computed via 
DPD 
0.825 0.825 0.716 0.771 
Post-tx WHO risk: moderate risk or lower risk 
computed via DDD 
0.831 0.821 0.814 0.781 
Post-tx WHO risk: moderate risk or lower risk 
computed via MXD 
0.841 0.835 0.819 0.780 
Post-tx WHO risk: moderate risk or lower risk 
computed via DPD 
0.859 0.842 0.853 0.821 
Post-tx Composite clinical Outcome: Abstinent 0.846 0.834 0.801 0.784 
Post-tx Composite clinical Outcome: Moderate 
drinking or abstinent 
0.921 0.909 0.914 0.870 
Post-tx Composite clinical Outcome: Heavy drinking 
OR problems, moderate drinking, or abstinent 
0.944 0.939 0.939 0.917 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.701 0.692 0.687 0.673 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.691 0.687 0.677 0.655 
2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.731 0.722 0.713 0.688 
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2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.677 0.677 0.663 0.642 
12mo Abstinence 0.684 0.671 0.659 0.645 
12mo Heavy Drinking 0.702 0.685 0.683 0.674 
12mo WHO risk: low risk or lower risk computed via 
DDD 
0.705 0.696 0.681 0.663 
12mo WHO risk: low risk or lower risk computed via 
MXD 
0.712 0.702 0.685 0.669 
12mo WHO risk: low risk or lower risk computed via 
DPD 
0.710 0.711 0.688 0.662 
12mo WHO risk: moderate risk or lower risk computed 
via DDD 
0.699 0.688 0.683 0.668 
12mo WHO risk: moderate risk or lower risk computed 
via MXD 
0.700 0.686 0.681 0.670 
12mo WHO risk: moderate risk or lower risk computed 
via DPD 
0.712 0.709 0.692 0.677 
12mo Composite clinical Outcome: Abstinent 0.705 0.694 0.689 0.663 
12mo Composite clinical Outcome: Moderate drinking 
or abstinent 
0.736 0.719 0.715 0.699 
12mo Composite clinical Outcome: Heavy drinking OR 
problems, moderate drinking, or abstinent 
0.755 0.748 0.747 0.727 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability.  
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Table 14 
Receiver operating characteristic curve area under the curve (AUC) results for the Drinker Inventory of Consequences (DrInC) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in Project MATCH 
 
MATCH DrInC total 
score 
Factor 1 
(Common 
Consequences) 
Factor 2 
(Moderately 
Common 
Consequences) 
Factor 3 (Rare 
Consequences) 
Post-tx Abstinence 0.583 0.585 0.573 0.586 
Post-tx Heavy Drinking 0.679 0.672 0.673 0.671 
Post-tx WHO risk: low risk or lower risk computed via 
DDD 
0.658 0.650 0.651 0.654 
Post-tx WHO risk: low risk or lower risk computed via 
MXD 
0.642 0.637 0.635 0.639 
Post-tx WHO risk: low risk or lower risk computed via 
DPD 
0.675 0.747 0.756 0.718 
Post-tx WHO risk: moderate risk or lower risk 
computed via DDD 
0.688 0.678 0.683 0.680 
Post-tx WHO risk: moderate risk or lower risk 
computed via MXD 
0.677 0.669 0.671 0.671 
Post-tx WHO risk: moderate risk or lower risk 
computed via DPD 
0.784 0.778 0.787 0.737 
Post-tx Composite clinical Outcome: Abstinent 0.652 0.649 0.647 0.631 
Post-tx Composite clinical Outcome: Moderate 
drinking or abstinent 
0.886 0.850 0.879 0.876 
Post-tx Composite clinical Outcome: Heavy drinking 
OR problems, moderate drinking, or abstinent 
0.836 0.812 0.835 0.809 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.579 0.590 0.589 0.597 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.549 0.541 0.550 0.568 
2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.550 0.558 0.554 0.569 
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2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.493 0.508 0.495 0.513 
12mo Abstinence 0.424 0.432 0.425 0.436 
12mo Heavy Drinking 0.511 0.515 0.511 0.509 
12mo WHO risk: low risk or lower risk computed via 
DDD 
0.499 0.505 0.496 0.504 
12mo WHO risk: low risk or lower risk computed via 
MXD 
0.470 0.473 0.468 0.478 
12mo WHO risk: low risk or lower risk computed via 
DPD 
0.557 0.569 0.561 0.535 
12mo WHO risk: moderate risk or lower risk computed 
via DDD 
0.547 0.553 0.543 0.546 
12mo WHO risk: moderate risk or lower risk computed 
via MXD 
0.507 0.517 0.506 0.508 
12mo WHO risk: moderate risk or lower risk computed 
via DPD 
0.575 0.581 0.582 0.547 
12mo Composite clinical Outcome: Abstinent 0.453 0.465 0.455 0.462 
12mo Composite clinical Outcome: Moderate drinking 
or abstinent 
0.558 0.566 0.558 0.549 
12mo Composite clinical Outcome: Heavy drinking OR 
problems, moderate drinking, or abstinent 
0.590 0.598 0.589 0.573 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability. 
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Table 15 
Receiver operating characteristic curve area under the curve (AUC) results for the baseline Spielberger State-Trait Inventory (SSTI) 
for detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes  
 
SSTI total 
score 
SSTI total 
score 
(CFA 
items 
only) 
“Factor 1” 
by Forgays 
et al., 1997 
“Factor 2” 
by Forgays 
et al., 1997 
“Factor 4” 
by Forgays 
et al., 1997 
“Factor 6” 
by Forgays 
et al., 1997 
Post-tx Abstinence 0.524 0.526 0.514 0.529 0.524 0.500 
Post-tx Heavy Drinking 0.549 0.548 0.538 0.544 0.546 0.518 
Post-tx WHO risk: low risk or 
lower risk computed via DDD 
0.540 0.540 0.536 0.539 0.539 0.508 
Post-tx WHO risk: low risk or 
lower risk computed via MXD 
0.530 0.530 0.523 0.533 0.530 0.502 
Post-tx WHO risk: low risk or 
lower risk computed via DPD 
0.565 0.564 0.564 0.539 0.568 0.531 
Post-tx WHO risk: moderate risk or 
lower risk computed via DDD 
0.555 0.554 0.550 0.546 0.541 0.523 
Post-tx WHO risk: moderate risk or 
lower risk computed via MXD 
0.548 0.547 0.535 0.543 0.543 0.520 
Post-tx WHO risk: moderate risk or 
lower risk computed via DPD 
0.577 0.575 0.560 0.543 0.568 0.554 
Post-tx Composite clinical 
Outcome: Abstinent 
0.534 0.534 0.511 0.539 0.530 0.516 
Post-tx Composite clinical 
Outcome: Moderate drinking or 
abstinent 
0.563 0.562 0.538 0.553 0.552 0.543 
Post-tx Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, or 
abstinent 
0.569 0.567 0.553 0.534 0.576 0.550 
1 or more risk level change in 0.562 0.561 0.564 0.541 0.548 0.540 
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WHO risk level baseline to post-tx 
(computed via DDD) 
1 or more risk level change in 
WHO risk level baseline to post-tx 
(computed via DPD) 
0.546 0.548 0.547 0.555 0.523 0.524 
2 or more risk level change in 
WHO risk level baseline to post-tx 
(computed via DDD) 
0.536 0.537 0.539 0.532 0.533 0.515 
2 or more risk level change in 
WHO risk level baseline to post-tx 
(computed via DPD) 
0.503 0.504 0.510 0.516 0.492 0.491 
12mo Abstinence 0.499 0.501 0.501 0.501 0.507 0.490 
12mo Heavy Drinking 0.518 0.521 0.530 0.513 0.528 0.495 
12mo WHO risk: low risk or lower 
risk computed via DDD 
0.511 0.513 0.517 0.510 0.518 0.493 
12mo WHO risk: low risk or lower 
risk computed via MXD 
0.509 0.511 0.512 0.510 0.514 0.496 
12mo WHO risk: low risk or lower 
risk computed via DPD 
0.530 0.532 0.545 0.524 0.534 0.501 
12mo WHO risk: moderate risk or 
lower risk computed via DDD 
0.532 0.533 0.540 0.527 0.529 0.503 
12mo WHO risk: moderate risk or 
lower risk computed via MXD 
0.520 0.522 0.528 0.517 0.528 0.495 
12mo WHO risk: moderate risk or 
lower risk computed via DPD 
0.547 0.548 0.545 0.537 0.548 0.514 
12mo Composite clinical Outcome: 
Abstinent 
0.506 0.509 0.512 0.509 0.505 0.497 
12mo Composite clinical Outcome: 
Moderate drinking or abstinent 
0.534 0.535 0.536 0.525 0.541 0.512 
12mo Composite clinical Outcome: 
Heavy drinking OR problems, 
moderate drinking, or abstinent 
0.559 0.561 0.552 0.532 0.563 0.539 
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Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability. 
  
106 
 
 
Table 16 
Receiver operating characteristic curve area under the curve (AUC) results for the Health Survey (SF-12) for detecting/discriminating 
post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes  
 SF-12 total score Physical Factor Psychological Factor 
Post-tx Abstinence 0.624 0.578 0.637 
Post-tx Heavy Drinking 0.671 0.610 0.686 
Post-tx WHO risk: low risk or lower risk computed via 
DDD 
0.654 0.598 0.667 
Post-tx WHO risk: low risk or lower risk computed via 
MXD 
0.646 0.586 0.663 
Post-tx WHO risk: low risk or lower risk computed via 
DPD 
0.701 0.652 0.695 
Post-tx WHO risk: moderate risk or lower risk computed 
via DDD 
0.677 0.632 0.681 
Post-tx WHO risk: moderate risk or lower risk computed 
via MXD 
0.672 0.615 0.684 
Post-tx WHO risk: moderate risk or lower risk computed 
via DPD 
0.724 0.672 0.724 
Post-tx Composite clinical Outcome: Abstinent 0.633 0.593 0.641 
Post-tx Composite clinical Outcome: Moderate drinking 
or abstinent 0.754 0.707 0.745 
Post-tx Composite clinical Outcome: Heavy drinking OR 
problems, moderate drinking, or abstinent 0.836 0.766 0.840 
1 or more risk level change in WHO risk level baseline to 
post-tx (computed via DDD) 
0.601 0.574 0.611 
1 or more risk level change in WHO risk level baseline to 
post-tx (computed via DPD) 
0.577 0.522 0.603 
2 or more risk level change in WHO risk level baseline to 
post-tx (computed via DDD) 
0.601 0.560 0.616 
2 or more risk level change in WHO risk level baseline to 
post-tx (computed via DPD) 
0.578 0.529 0.600 
12mo Abstinence 0.548 0.518 0.561 
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12mo Heavy Drinking 0.595 0.562 0.604 
12mo WHO risk: low risk or lower risk computed via 
DDD 
0.599 0.562 0.608 
12mo WHO risk: low risk or lower risk computed via 
MXD 
0.592 0.557 0.601 
12mo WHO risk: low risk or lower risk computed via 
DPD 
0.630 0.586 0.637 
12mo WHO risk: moderate risk or lower risk computed 
via DDD 
0.609 0.580 0.614 
12mo WHO risk: moderate risk or lower risk computed 
via MXD 
0.603 0.570 0.608 
12mo WHO risk: moderate risk or lower risk computed 
via DPD 
0.632 0.593 0.635 
12mo Composite clinical Outcome: Abstinent 0.561 0.540 0.565 
12mo Composite clinical Outcome: Moderate drinking or 
abstinent 0.632 0.590 0.636 
12mo Composite clinical Outcome: Heavy drinking OR 
problems, moderate drinking, or abstinent 0.681 0.627 0.693 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability. 
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Table 17 
Receiver operating characteristic curve area under the curve (AUC) results for the Psychosocial Functioning Inventory (PFI) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes 
 PFI total score 
Subjective 
Role 
Performance 
Factor 
Overall Social 
Role 
Performance 
Factor 
Housemate/ 
Roommate 
Factor 
Post-tx Abstinence 0.608 0.545 0.575 0.575 
Post-tx Heavy Drinking 0.646 0.599 0.617 0.604 
Post-tx WHO risk: low risk or lower risk computed via 
DDD 
0.642 0.588 0.608 0.613 
Post-tx WHO risk: low risk or lower risk computed via 
MXD 
0.631 0.571 0.593 0.601 
Post-tx WHO risk: low risk or lower risk computed via 
DPD 
0.671 0.630 0.625 0.660 
Post-tx WHO risk: moderate risk or lower risk 
computed via DDD 
0.651 0.610 0.626 0.611 
Post-tx WHO risk: moderate risk or lower risk 
computed via MXD 
0.644 0.596 0.614 0.602 
Post-tx WHO risk: moderate risk or lower risk 
computed via DPD 
0.700 0.644 0.663 0.658 
Post-tx Composite clinical Outcome: Abstinent 0.611 0.559 0.579 0.573 
Post-tx Composite clinical Outcome: Moderate 
drinking or abstinent 
0.648 0.611 0.599 0.614 
Post-tx Composite clinical Outcome: Heavy drinking 
OR problems, moderate drinking, or abstinent 
0.665 0.626 0.637 0.613 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.595 0.598 0.580 0.587 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.574 0.556 0.552 0.552 
2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.584 0.577 0.571 0.571 
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2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.538 0.522 0.520 0.537 
12mo Abstinence 0.553 0.517 0.531 0.538 
12mo Heavy Drinking 0.591 0.552 0.551 0.577 
12mo WHO risk: low risk or lower risk computed via 
DDD 
0.586 0.546 0.549 0.568 
12mo WHO risk: low risk or lower risk computed via 
MXD 
0.574 0.532 0.537 0.554 
12mo WHO risk: low risk or lower risk computed via 
DPD 
0.581 0.554 0.540 0.569 
12mo WHO risk: moderate risk or lower risk computed 
via DDD 
0.596 0.568 0.559 0.579 
12mo WHO risk: moderate risk or lower risk computed 
via MXD 
0.589 0.554 0.548 0.572 
12mo WHO risk: moderate risk or lower risk computed 
via DPD 
0.574 0.576 0.542 0.563 
12mo Composite clinical Outcome: Abstinent 0.565 0.523 0.538 0.545 
12mo Composite clinical Outcome: Moderate drinking 
or abstinent 
0.600 0.573 0.583 0.571 
12mo Composite clinical Outcome: Heavy drinking OR 
problems, moderate drinking, or abstinent 
0.597 0.582 0.585 0.564 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability.  
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Table 18 
Receiver operating characteristic curve area under the curve (AUC) results for the Alcohol Abstinence Self-Efficacy (AASE) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in the COMBINE Study 
 
COMBINE 
AASE total 
score 
AASE 
Confidence 
Subscale 
AASE 
Temptation 
Subscale 
Negative 
Affect 
Factor 
Social 
Factor 
Physical 
Factor 
Urge 
Factor 
Post-tx Abstinence 0.583 0.793 0.790 0.561 0.507 0.592 0.574 
Post-tx Heavy Drinking 0.592 0.804 0.790 0.569 0.531 0.599 0.576 
Post-tx WHO risk: low risk or 
lower risk computed via DDD 
0.589 0.796 0.788 0.568 0.521 0.588 0.578 
Post-tx WHO risk: low risk or 
lower risk computed via MXD 
0.593 0.808 0.804 0.566 0.513 0.592 0.587 
Post-tx WHO risk: low risk or 
lower risk computed via DPD 
0.593 0.814 0.799 0.571 0.554 0.585 0.580 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DDD 
0.601 0.790 0.766 0.574 0.551 0.600 0.580 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
MXD 
0.590 0.796 0.784 0.566 0.521 0.597 0.577 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DPD 
0.625 0.845 0.810 0.615 0.580 0.590 0.601 
Post-tx Composite clinical 
Outcome: Abstinent 
0.579 0.787 0.790 0.570 0.498 0.587 0.568 
Post-tx Composite clinical 
Outcome: Moderate drinking 
or abstinent 
0.593 0.867 0.858 0.569 0.554 0.592 0.572 
Post-tx Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0.620 0.879 0.852 0.618 0.564 0.621 0.578 
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1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.554 0.674 0.669 0.545 0.530 0.548 0.547 
1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.547 0.699 0.698 0.535 0.535 0.537 0.547 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.546 0.711 0.719 0.527 0.504 0.553 0.537 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.544 0.691 0.688 0.527 0.509 0.550 0.542 
12mo Abstinence 0.516 0.664 0.690 0.509 0.459 0.532 0.521 
12mo Heavy Drinking 0.542 0.687 0.701 0.529 0.478 0.543 0.541 
12mo WHO risk: low risk or 
lower risk computed via DDD 
0.532 0.685 0.709 0.510 0.474 0.538 0.538 
12mo WHO risk: low risk or 
lower risk computed via MXD 
0.523 0.692 0.717 0.505 0.465 0.534 0.531 
12mo WHO risk: low risk or 
lower risk computed via DPD 
0.557 0.698 0.707 0.531 0.509 0.543 0.554 
12mo WHO risk: moderate 
risk or lower risk computed via 
DDD 
0.548 0.683 0.692 0.523 0.500 0.543 0.547 
12mo WHO risk: moderate 
risk or lower risk computed via 
MXD 
0.537 0.683 0.700 0.515 0.476 0.541 0.540 
12mo WHO risk: moderate 
risk or lower risk computed via 
DPD 
0.549 0.715 0.724 0.526 0.496 0.540 0.547 
12mo Composite clinical 
Outcome: Abstinent 
0.550 0.698 0.708 0.535 0.480 0.562 0.555 
12mo Composite clinical 0.577 0.732 0.734 0.558 0.507 0.568 0.576 
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Outcome: Moderate drinking 
or abstinent 
12mo Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0.597 0.729 0.723 0.572 0.541 0.588 0.580 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability. 
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Table 19 
Receiver operating characteristic curve area under the curve (AUC) results for the Alcohol Abstinence Self-Efficacy (AASE) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in Project MATCH 
 
MATCH 
AASE total 
score 
AASE 
Confidence 
Subscale 
AASE 
Temptation 
Subscale 
Negative 
Affect 
Factor 
Social 
Factor 
Physical 
Factor 
Urge 
Factor 
Post-tx Abstinence 0.573 0.720 0.703 0.527 0.533 0.576 0.578 
Post-tx Heavy Drinking 0.554 0.726 0.735 0.501 0.519 0.554 0.554 
Post-tx WHO risk: low risk or 
lower risk computed via DDD 
0.563 0.726 0.722 0.507 0.529 0.564 0.564 
Post-tx WHO risk: low risk or 
lower risk computed via MXD 
0.562 0.725 0.721 0.512 0.523 0.566 0.567 
Post-tx WHO risk: low risk or 
lower risk computed via DPD 
0.532 0.730 0.758 0.471 0.528 0.538 0.544 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DDD 
0.539 0.716 0.735 0.485 0.512 0.543 0.541 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
MXD 
0.553 0.726 0.735 0.502 0.517 0.553 0.554 
Post-tx WHO risk: moderate 
risk or lower risk computed via 
DPD 
0.523 0.733 0.767 0.475 0.519 0.531 0.533 
Post-tx Composite clinical 
Outcome: Abstinent 
0.550 0.701 0.702 0.511 0.524 0.560 0.550 
Post-tx Composite clinical 
Outcome: Moderate drinking 
or abstinent 
0.542 0.720 0.735 0.492 0.516 0.563 0.542 
Post-tx Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0.540 0.717 0.735 0.483 0.514 0.550 0.542 
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1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.534 0.668 0.626 0.502 0.517 0.537 0.534 
1 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.545 0.628 0.565 0.515 0.529 0.555 0.534 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DDD) 
0.543 0.685 0.537 0.503 0.515 0.552 0.544 
2 or more risk level change in 
WHO risk level baseline to 
post-tx (computed via DPD) 
0.536 0.611 0.572 0.520 0.512 0.547 0.529 
12mo Abstinence 0.555 0.666 0.655 0.524 0.512 0.568 0.556 
12mo Heavy Drinking 0.536 0.667 0.674 0.499 0.511 0.545 0.534 
12mo WHO risk: low risk or 
lower risk computed via DDD 
0.543 0.681 0.681 0.505 0.509 0.552 0.542 
12mo WHO risk: low risk or 
lower risk computed via MXD 
0.544 0.672 0.670 0.510 0.508 0.556 0.546 
12mo WHO risk: low risk or 
lower risk computed via DPD 
0.540 0.689 0.700 0.497 0.517 0.551 0.544 
12mo WHO risk: moderate 
risk or lower risk computed via 
DDD 
0.534 0.682 0.694 0.494 0.516 0.544 0.528 
12mo WHO risk: moderate 
risk or lower risk computed via 
MXD 
0.538 0.675 0.681 0.502 0.511 0.547 0.535 
12mo WHO risk: moderate 
risk or lower risk computed via 
DPD 
0.522 0.672 0.700 0.504 0.514 0.524 0.513 
12mo Composite clinical 
Outcome: Abstinent 
0.556 0.689 0.679 0.520 0.519 0.563 0.550 
12mo Composite clinical 0.537 0.690 0.712 0.493 0.504 0.553 0.531 
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Outcome: Moderate drinking 
or abstinent 
12mo Composite clinical 
Outcome: Heavy drinking OR 
problems, moderate drinking, 
or abstinent 
0.503 0.649 0.696 0.465 0.501 0.516 0.500 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability.  
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Table 20 
Receiver operating characteristic curve area under the curve (AUC) results for the Addiction Severity Index (ASI) for 
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes 
 ASI total score 
Post-tx Abstinence 0.551 
Post-tx Heavy Drinking 0.568 
Post-tx WHO risk: low risk or lower risk computed 
via DDD 
0.569 
Post-tx WHO risk: low risk or lower risk computed 
via MXD 
0.559 
Post-tx WHO risk: low risk or lower risk computed 
via DPD 
0.599 
Post-tx WHO risk: moderate risk or lower risk 
computed via DDD 
0.583 
Post-tx WHO risk: moderate risk or lower risk 
computed via MXD 
0.568 
Post-tx WHO risk: moderate risk or lower risk 
computed via DPD 
0.612 
Post-tx Composite clinical Outcome: Abstinent 0.538 
Post-tx Composite clinical Outcome: Moderate 
drinking or abstinent 
0.562 
Post-tx Composite clinical Outcome: Heavy 
drinking OR problems, moderate drinking, or 
abstinent 
0.573 
1 or more risk level change in WHO risk level 
baseline to post-tx (computed via DDD) 
0.528 
1 or more risk level change in WHO risk level 
baseline to post-tx (computed via DPD) 
0.514 
2 or more risk level change in WHO risk level 
baseline to post-tx (computed via DDD) 
0.510 
2 or more risk level change in WHO risk level 
baseline to post-tx (computed via DPD) 
0.494 
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12mo Abstinence 0.504 
12mo Heavy Drinking 0.515 
12mo WHO risk: low risk or lower risk computed 
via DDD 
0.514 
12mo WHO risk: low risk or lower risk computed 
via MXD 
0.508 
12mo WHO risk: low risk or lower risk computed 
via DPD 
0.523 
12mo WHO risk: moderate risk or lower risk 
computed via DDD 
0.525 
12mo WHO risk: moderate risk or lower risk 
computed via MXD 
0.515 
12mo WHO risk: moderate risk or lower risk 
computed via DPD 
0.492 
12mo Composite clinical Outcome: Abstinent 0.511 
12mo Composite clinical Outcome: Moderate 
drinking or abstinent 
0.535 
12mo Composite clinical Outcome: Heavy drinking 
OR problems, moderate drinking, or abstinent 
0.544 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability. 
  
118 
 
 
Table 21 
Receiver operating characteristic curve area under the curve (AUC) results for percent days abstinent (PDA) and percent heavy 
drinking days (PHDD) for detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in 
the COMBINE Study and Project MATCH 
 COMBINE PDA 
COMBINE 
PHDD 
MATCH PDA 
MATCH 
PHDD 
Post-tx Abstinence - 0.880 - 0.897 
Post-tx Heavy Drinking 0.900 - 0.955 - 
Post-tx WHO risk: low risk or lower risk computed via 
DDD 
0.922 0.937 0.962 0.945 
Post-tx WHO risk: low risk or lower risk computed via 
MXD 
0.962 0.919 0.979 0.944 
Post-tx WHO risk: low risk or lower risk computed via 
DPD 
0.960 0.955 0.971 0.983 
Post-tx WHO risk: moderate risk or lower risk 
computed via DDD 
0.849 0.970 0.929 0.987 
Post-tx WHO risk: moderate risk or lower risk 
computed via MXD 
0.909 0.986 0.958 0.994 
Post-tx WHO risk: moderate risk or lower risk 
computed via DPD 
0.954 0.988 0.970 0.990 
Post-tx Composite clinical Outcome: Abstinent 0.975 0.846 0.882 0.803 
Post-tx Composite clinical Outcome: Moderate 
drinking or abstinent 
0.946 0.960 0.872 0.844 
Post-tx Composite clinical Outcome: Heavy drinking 
OR problems, moderate drinking, or abstinent 
0.876 0.902 0.834 0.849 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.670 0.726 0.698 0.672 
1 or more risk level change in WHO risk level baseline 
to post-tx (computed via DPD) 
0.724 0.731 0.682 0.611 
2 or more risk level change in WHO risk level baseline 
to post-tx (computed via DDD) 
0.757 0.753 0.745 0.679 
2 or more risk level change in WHO risk level baseline 0.745 0.732 0.666 0.610 
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to post-tx (computed via DPD) 
12mo Abstinence 0.806 0.682 0.724 0.668 
12mo Heavy Drinking 0.736 0.740 0.721 0.703 
12mo WHO risk: low risk or lower risk computed via 
DDD 
0.753 0.719 0.726 0.695 
12mo WHO risk: low risk or lower risk computed via 
MXD 
0.773 0.709 0.728 0.686 
12mo WHO risk: low risk or lower risk computed via 
DPD 
0.798 0.768 0.748 0.724 
12mo WHO risk: moderate risk or lower risk computed 
via DDD 
0.719 0.742 0.711 0.709 
12mo WHO risk: moderate risk or lower risk computed 
via MXD 
0.737 0.734 0.723 0.700 
12mo WHO risk: moderate risk or lower risk computed 
via DPD 
0.773 0.778 0.733 0.727 
12mo Composite clinical Outcome: Abstinent 0.773 0.686 0.743 0.688 
12mo Composite clinical Outcome: Moderate drinking 
or abstinent 
0.787 0.756 0.754 0.724 
12mo Composite clinical Outcome: Heavy drinking OR 
problems, moderate drinking, or abstinent 
0.716 0.723 0.694 0.683 
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in 
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved 
readability. 
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Appendix A 
Individual Item Receiver Operating Characteristic Curve Results 
 Brief Symptom Inventory. Since ROC curve analyses for the BSI total and subscale 
score yielded AUC’s > 0.650, ROC curve analyses were conducted for individual items. Items 1 
(nervousness or shakiness; Anxiety subscale item), 15 (feeling blocked in getting things done; 
Obsessive-Compulsive subscale item), and 17 (feeling blue; Depression subscale item) 
adequately detected 4 of 15 post-treatment outcomes: WHO low or lower risk level (calculated 
via DPD; AUC = 0.687, 0.687, 0.674), WHO moderate or lower risk level (calculated via DPD; 
AUC = 0.720, 0.684, 0.704), composite clinical outcome of moderate or lower risk (AUC = 
0.717, 0.686, 0.706), and composite clinical outcome of heavy or lower risk (AUC = 0.772, 
0.767, 0.786). Items 6 (annoyed or irritated; Hostility subscale item), 18 (lack of interest; 
Depression subscale item), 19 (feeling fearful; Anxiety subscale item), 36 (trouble concentrating; 
Obsessive-Compulsive subscale item), and 38 (tense/keyed up; Anxiety subscale item) all 
adequately detected 3 of 15 post-treatment outcomes: WHO moderate or lower risk level 
(calculated via DPD; AUC = 0.683, 0.660, 0.656, 0.672, 0.669), composite clinical outcome of 
moderate or lower risk (AUC = 0.677, 0.678, 0.650, 0.670, 0.670), and composite clinical 
outcome of heavy or lower risk (AUC = 0.768, 0.760, 0.697, 0.751, 0.738). In addition to the 
above items, post-treatment composite clinical outcome of moderate or lower risk and composite 
clinical outcome of heavy or lower risk were also both adequately detected by item 5 (trouble 
remembering; Obsessive-Compulsive subscale item; AUC’s = 0.667, 0.678), item14 (feeling 
lonely; Psychoticism subscale item; AUC’s = 0.653, 0.710), item 16 (feeling lonely; Depression 
subscale item; AUC’s = 0.686, 0.763), item 35 (hopeless; Depression subscale item; AUC’s = 
0.674, 0.758), item 50 (worthlessness; Depression subscale item; AUC’s = 0.659, 0.724), and 
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items 52 (guilt; Interpersonal Sensitivity subscale item; AUC’s = 0.683, 0.737) and 53 (ideas 
something is wrong with you; Psychoticism subscale item; AUC’s = 0.677, 0.747). Post 
treatment composite clinical outcome of heavy or lower risk was also adequately detected by 15 
other items, which made it the most readily detected post-treatment consumption outcome. 
Moreover, 12-month follow-up composite clinical outcome of heavy or lower risk was the only 
12-month follow-up consumption outcome that was adequately detected by any BSI individual 
items and it was adequately detected by 7 items: 6 (annoyed or irritated; Hostility subscale item), 
15 (feeling blocked in getting things done; Obsessive-Compulsive subscale item), 16 (feeling 
lonely; Depression subscale item), 17 (feeling blue; Depression subscale item), 18 (lack of 
interest; Depression subscale item), 52 (guilt; Interpersonal Sensitivity subscale item), and 53 
(ideas something is wrong with you; Psychoticism subscale item). 
 World Health Organization Quality of Life, Brief Version. Since ROC curve analyses 
for the week 26 WHOQOL-BREF subscales yielded adequate detection of 12-month 
consumption outcomes (AUC’s > 0.650), analyses were conducted for individual items of the 
week 26 WHOQOL-BREF for detecting 12-month consumption outcomes. The 12-month 
composite clinical outcome of heavy or lower risk was adequately detected by 8 of the individual 
items: item 5 (enjoy life; Psychological Health subscale item; AUC = 0.675), item 6 (life is 
meaningful; Psychological Health subscale item; AUC = 0.665), item 7 (able to concentrate; 
Psychological Health subscale item; AUC = 0.655), item 16 (sleep satisfaction; Physical Health 
subscale item; AUC = 0.661), item 17 (daily activities; Physical Health subscale item; AUC = 
0.696), item 18 (capacity for work; Physical Health subscale item; AUC = 0.650), item 20 
(personal relationships; Social subscale item; AUC = 0.673), and item 22 (friend support; Social 
subscale item; AUC = 0.654). 
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 Beck Depression Inventory. Since the BDI subscales adequately detected some post-
treatment consumption outcomes, ROC curve analyses were conducted for individual items’ 
ability to detect post-treatment outcomes. The outcomes that were adequately detected were 
WHO low or lower risk level (calculated via DPD; WLLP) and WHO moderate or lower risk 
level (calculated via DPD; WMLP). Items 4 (satisfaction in activities) and 7 (self-dislike) were 
able to adequately detect both of these outcomes: WLLP (AUC’s = 0.670, 0.671) and WMLP 
(AUC’s = 0.674, 0.683). Item 15 (work ability) was only able to adequately detect post-treatment 
WLLP (AUC = 0.650). Items 3 (personal failure), 5 (guilt), and 16 (sleep disturbance) were all 
able to adequately detect post-treatment WMLP (AUC’s = 0.664, 0.661, 0.660). 
 Obsessive-Compulsive Drinking Scale. Given how well each sub-factor of the OCDS 
did in ROC curve analyses, it is unsurprising individual items also performed well. Items 13 
(drive to consume), and 14 (control over drinking) all adequately detected 15 of 15 post-
treatment outcomes: AUC’s = 0.650-0.880, and 0.664-0.894. Item 12 (effort to resist drinking) 
adequately detected 13 of 15 post-treatment outcomes: AUC’s = 0.624-0.845. Items 5 (effort to 
resist thoughts), 6 (success in stopping thoughts), and 11 (anxiety over being prevented from 
drinking) each adequately detected 12 of 15 post-treatment outcomes: AUC’s = 0.610-0.848, 
0.635-0.848, 0.640-0.867). Items 1 (time thinking) and 4 (distress of thoughts) each adequately 
detected 11 of 15 whereas item 10 (social functioning interference) adequately detected 10 of 15 
post-treatment outcomes: AUC’s = 0.590-0.787, 0.574-0.806 and 0.598-0.853. Item 9 (work 
functioning interference) adequately detected 8 of 15 post-treatment outcomes (AUC’s = 0.584-
0.811) and items 2 (thought frequency) and 3 (thought interference with social or work 
functioning) each adequately detected 3 of 15 post-treatment outcomes: AUC’s = 0.576-0.718, 
0.556-0.789. For 12-month follow-up outcomes, items 7 and 8 adequately detected 11 of 11 
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outcomes (AUC’s = 0.672-0.737, 0.661-0.740); items 13 and 14 adequately detected 9 of 11 
outcomes (AUC’s = 0.644-0.696, 0.647-0.704). Items 6, 11, and 12 each adequately detected 8 
of 11 outcomes: AUC’s = 0.632-0.690, 0.642-0.698, and 0.639-0.690. Item 5 adequately 
detected 2 of 11 12-month outcomes (AUC’s = 0.608-0.678) and items 1 and 4 adequately 
detected 1 of 11 12-month outcomes: AUC’s = 0.602-0.668, 0.573-0.667. Post-treatment 
outcomes of composite clinical outcome of heavy or lower risk and 2+ change in WHO risk level 
since baseline (calculated via DPD) were the most and least detectable consumption outcomes 
for 9 of the 14 of individual items. For items that were able to adequately detect at least one 12-
month outcome (AUC > 0.650), composite clinical outcome of moderate or lower risk and 
composite clinical outcome of heavy or lower risk yielded the highest AUC’s; abstinence and 
WHO moderate or lower risk (calculated via MXD) yielded the lowest AUC’s. 
 Drinker Inventory of Consequences. The 3 factors that were upheld via CFA and 
measurement invariance testing for the DrInC in both COMBINE and MATCH yielded high 
AUC values in ROC curve analyses. Therefore, individual item ROC curve analyses were 
conducted for COMBINE and MATCH DrInC data.  
 In COMBINE, several individual items were able to adequately detect post-treatment 
outcomes. Items 1 and 2 (hangover, felt bad about self) adequately detected all post-treatment 
outcomes (AUC’s = 0.664-0.880, 0.651-0.870); item 12 (unhappy due to drinking) adequately 
detected 14 of 15 post-treatment outcomes (AUC’s = 0.640-0.898). Item 16 (guilt/ashamed; 
AUC’s = 0.630-0.881) adequately detected 13 of 15 post-treatment outcomes. Several individual 
items were able to adequately detect 11 of 15 post-treatment outcomes: item 4 (family/friends 
worried/complained; AUC’s = 0.602-0.805), item 8 (sleep disturbances; AUC’s = 0.578-0.833), 
item 13 (eating disturbances; AUC’s = 0.597-0.888), item 18 (personality worsened; AUC’s = 
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0.587-0.794), item 37 (undesired life; AUC’s = 0.607-0.883), and item 38 (personal growth 
interference; AUC’s = 0.619-0.895). Item 28 (smoked more tobacco) adequately detected 10 of 
15 post-treatment outcomes (AUC’s = 0.589-0.742); item 17 (said/done embarrassing things) 
adequately detected 9 of 15 post-treatment outcomes (AUC’s = 0.591-0.804). Item 40 (spent too 
much money) adequately detected 8 out of 15 post-treatment outcomes (AUC’s = 0.576-0.821). 
Many items adequately detected 7 out of 15 post-treatment outcomes: item 14 (failed 
expectations; AUC’s = 0.555-0.831), item 24 (physical health harmed; AUC’s = .593-0.838), 
item 30 (hurt family; AUC’s = 0.560-0.784), item 34 (lost interest; AUC’s = 0.576-0.823), and 
item 36 (spiritual/moral life harmed; AUC’s = 0.583-0.794). Items 22 (impulsivity) and 39 
(damaged social life) adequately detected 5 of 15 post-treatment outcomes (AUC’s = 0.569-
0.818, 0.555-0.794). Four items adequately detected 4 of 15 post-treatment outcomes: item 6 
(work quality suffered; AUC’s = 0.582-0.801), item 9 (driven after 3+ drinks; AUC’s = 0.594-
0.744), item 29 (physical appearance harmed; AUC’s = 0.567-0.842), and item 33 (sex life 
suffered; AUC’s = 0.569-0.776). Six items each adequately detected 3 of 15 post-treatment 
outcomes: item 19 (foolish risks; AUC’s = 0.555-0.777), item 21 (said cruel things; AUC’s = 
0.562-0.710), item 26 (money problems; AUC’s = 0.564-0.774), item 27 (marriage/love 
relationship harmed; AUC’s = 0.559-0.717), item 31 (friendship damaged; AUC’s = 0.557-
0.751), and item 32 (overweight; AUC’s = 0.583-0.708). Item 20 (trouble; AUC’s = 0.527-
0.677) adequately detected 2 of 15 post-treatment outcomes; items 3 (missed school/work), item 
7 (parenting ability), and 11 (vomited) each adequately detected 1 of 15 post-treatment outcomes 
(AUC’s = 0.535-0.716, 0.535-0.684, 0.522-0.676). Items 10 (other drug use), 23 (physical fight), 
and 41 through 50 (arrested for DWI, trouble with the law, lost marriage/love relationship, 
suspended/fired, lost a friend, had an accident, been physically hurt, injured someone else, and 
125 
 
 
broken things) all failed to detect any post-treatment outcomes (0 out of 15 outcomes; AUC’s < 
0.650). 
 In COMBINE, some individual items of the DrInC also adequately detected 12-month 
follow-up outcomes. Item 1 (hangover) adequately detected all 11 out of 11 12-month outcomes 
(AUC’s = 0.663-0.698); item 2 (felt bad about self) adequately detected 10 of 11 12-month 
outcomes (AUC’s = 0.639-0.713). Item 16 (guilt/ashamed) adequately detected 9 of 11 12-month 
outcomes (AUC’s = 0.638-0.714); item 12 (unhappy due to drinking) adequately detected 6 of 11 
12-month outcomes (AUC’s = 0.629-0.707). These findings are consistent with the ability of 
these items to detect the majority of post-treatment outcomes. Additionally, item 38 (personal 
growth interference) adequately detected 2 of 11 12-month outcomes (AUC’s = 0.559-0.706) and 
several items adequately detected 1 of 11 12-month outcomes: item 8 (sleep disturbances), 13 
(eating disturbances), 18 (personality worsened), 24 (physical health harmed), 29 (physical 
appearance harmed), 30 (hurt family), 34 (lost interest), 36 (spiritual/moral life harmed), 37 
(undesired life), and 40 (spent too much money). 
 In MATCH, several individual items were able to detect any post-treatment outcomes. 
Item 1 (hangovers) adequately detected 9 out of the 11 post-treatment outcome tested (changes in 
WHO risk since baseline were not analyzed due to the null findings for total DrInC and 
individual factors for detecting those outcomes adequately; AUC’s = 0.596-0.733). Item 13 
(eating disturbances) adequately detected 7 of 11 post-treatment outcomes (AUC’s = 0.584-
0.768). Items 12 (unhappy due to drinking) and 17(said/done embarrassing things) adequately 
detected 6 of 11 post-treatment outcomes (AUC’s = 0.598-0.774, 0.575-0.771). Several items 
were able to adequately detect 4 of the 11 post-treatment outcomes examined: item 2 (felt bad 
about self ; AUC’s = 0.572-0.746), item 4 (family/friends worried/complained; AUC’s = 0.566-
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0.757), item 6 (work quality suffered; AUC’s = 0.548-0.685), item 8 (sleep disturbances; AUC’s 
= 0.521-0.719), item 14 (failed expectations; AUC’s = 0.550-0.757), item 16 (guilt/ashamed; 
AUC’s = 0.568-0.740), item 18 (personality worsened; AUC’s = 0.540-0.784), item 21 (said 
cruel things; AUC’s = 0.571-0.745), item 24 (physical health harmed; AUC’s = .563-0.755), 
item 26 (money problems; AUC’s = 0.551-0.733), item 29 (physical appearance harmed; AUC’s 
= 0.546-0.771), item 30 (hurt family; AUC’s = 0.551-0.772), item 34 (lost interest; AUC’s = 
0.535-0.753), item 36 (spiritual/moral life harmed; AUC’s = 0.518-0.719), item 37 (undesired 
life; AUC’s = 0.561-0.815), and item 38 (personal growth interference; AUC’s = 0.563-0.817), 
and item 40  (spent too much money; AUC’s = 0.581-0.778). Five individual items each 
adequately detected 3 of 11 post-treatment outcomes that were analyzed: item 9 (driven after 3+ 
drinks; AUC’s = 0.582-0.701), item 19 (foolish risks; AUC’s = 0.548-0.738), item 27 
(marriage/love relationship harmed; AUC’s = 0.542-0.740), item 31 (friendship damaged; 
AUC’s = 0.539-0.723), and item 39 (damaged social life; AUC’s = 0.509-0.752). Five items also 
detected only 2 of the 11 analyzed post-treatment items: item 20 (trouble; AUC’s = 0.540-0.675), 
item 22 (impulsivity; AUC’s = 0.540-0.727), item 28 (smoked more tobacco; AUC’s = 0.540-
0.721), and items 32 and 33 (overweight, AUC’s = 0.566-0.663; sex life suffered, AUC’s = 
0.513-0.687). Item 7 (parenting ability) was able to adequately detect 1 of the 11 examined post-
treatment outcomes (AUC’s = 0.537-0.657). All other items failed to adequately detect (AUC’s 
< 0.650) any post-treatment consumption outcomes. In MATCH, several individual items on the 
DrInC were most able to detect post-treatment composite clinical outcome of moderate or lower 
risk and were poorest at detecting post-treatment abstinence. 
 Health Survey (SF-12). Since some of the post-treatment outcomes were adequately 
detected by each of the factors, select ROC curve analyses were conducted for individual items 
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based on which consumption outcomes were adequately detected by each item’s respective 
factor. Item 6A (felt calm or peaceful) had the highest AUC values and adequately detected 8 out 
of 9 post-treatment outcomes that were examined (AUC’s = 0.647-0.769). Item 6A was also the 
only examined item that was able to adequately detect any 12-month follow-up outcome: AUC = 
0.650 for 12-month follow-up composite clinical outcome of heavy or lower risk. Items 4B 
(emotional interference with work/activities) and 6B (lots of energy) were able to adequately 
detect 4 post-treatment outcomes with positive AUC’s = 0.651-0.763 and 0.650-0.775. Items 1 
(general health), 4A (emotional interference with accomplishments)m and 6C 
(downhearted/depressed) adequately detected 3 post-treatment outcomes: positive AUC’s = 
0.656-0.773, 0.669-0.775, 0.654-0.715. Items 3A (physical health interference with 
accomplishments) and 7 (physical/emotional interference with social activities) adequately 
detected 2 post-treatment outcomes: positive AUC’s = 0.670-0.684, 0.650-0.713. Items 2A 
(health limit moderate activities), 2B (health limit climbing stairs), 3B (physical health limits 
work/activities times), and 5 (pain interference with work) were unable to detect any of the post-
treatment outcomes that were examined in the present study. 
 Psychosocial Functioning Inventory. Only the Social Role Performance and 
Housemate/Roommate Role factors yielded some adequate AUC values in ROC curve analyses. 
Accordingly, individual item ROC curve analyses were conducted only for items from these two 
factors for consumption outcomes that were adequately detected from the larger factor subscale 
scores (i.e., only certain post-treatment consumption outcomes, and none of the 12-month 
follow-up consumption outcomes since AUC’s were all < 0.650 for every factor subscale score). 
From individual item ROC curve analyses conducted based on positive Social Role Performance 
and Housemate/Roommate Role factors ROC curve analyses, only 2 items adequately detected 
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any consumption outcomes. Item 11 (spousal/mate overall role performance; Social Role 
Performance factor) adequately detected WHO moderate or lower risk level (calculated via DPD; 
AUC = 0.677) as did item 19 (housemate/roommate overall role performance, AUC = 0.658). 
These two items were the only examined items that detected any post-treatment or 12-month 
follow-up outcomes and each only adequately detected one consumption outcome (WHO 
moderate or lower risk level (calculated via DPD). 
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